[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2189
1. Chantry AD, Snowden JA, Craddock C, Peggs K, Roddie C, Craig JI, Orchard K, Towlson KE, Pearce RM, Marks DI, BSBMT Clinical Trials Committee: Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry study. Biol Blood Marrow Transplant; 2006 Dec;12(12):1310-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry study.
  • Relapsed acute myeloid leukemia (AML) in adults has a poor prognosis if treated with chemotherapy alone.
  • Cytogenetic data were available for 68% of the patients; of these, at diagnosis, 42% had good risk features, 57% had standard risk features, and 1% had poor risk features.
  • At 10 years, actuarial overall survival (OS) was 32%, progression-free survival (PFS) was 28%, and relapse rate (RR) was 57%.
  • OS was significantly related to M3 subtype (5-year OS, 66%; P = .005), patient age at diagnosis (P = .005) and transplantation (P = .026), and length of CR1, with greatest significance if the patient was dichotomized at CR1 duration of < 8 months or > or = 8 months (P = .0001).
  • [MeSH-major] Bone Marrow Transplantation / statistics & numerical data. Leukemia, Myeloid / surgery. Peripheral Blood Stem Cell Transplantation / statistics & numerical data. Salvage Therapy. Transplantation Conditioning / statistics & numerical data. Transplantation, Autologous / statistics & numerical data
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Age Factors. Aged. Busulfan / administration & dosage. Busulfan / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Follow-Up Studies. Great Britain / epidemiology. Humans. Kaplan-Meier Estimate. Male. Melphalan / administration & dosage. Melphalan / adverse effects. Middle Aged. Registries / statistics & numerical data. Remission Induction. Retrospective Studies. Risk Factors. Survival Analysis. Whole-Body Irradiation / statistics & numerical data

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17162213.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan; Q41OR9510P / Melphalan
  •  go-up   go-down


2. Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT, Marsh SG, Guethlein LA, Parham P, Miller JS, Weisdorf DJ: Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood; 2009 Jan 15;113(3):726-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.
  • Survival for patients with acute myeloid leukemia (AML) is limited by treatment-related mortality (TRM) and relapse after unrelated donor (URD) hematopoietic cell transplantation (HCT).
  • Multivariate analysis demonstrated a 30% improvement in the relative risk of relapse-free survival with B/x donors compared with A/A donors (RR: 0.70 [95% CI: 0.55-0.88]; P = .002).
  • B/x donors were associated with a higher incidence of chronic graft-versus-host disease (GVHD; RR: 1.51 [95% CI: 1.01-2.18]; P = .03), but not of acute GVHD, relapse, or TRM.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2002 Mar 15;295(5562):2097-100 [11896281.001]
  • [Cites] Am J Transplant. 2008 Jun;8(6):1312-7 [18444913.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13483-8 [14597723.001]
  • [Cites] J Immunol. 2004 Jan 1;172(1):644-50 [14688377.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1521-6 [14504099.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1923-30 [15191952.001]
  • [Cites] Immunol Today. 1990 Jul;11(7):237-44 [2201309.001]
  • [Cites] Nature. 1997 Apr 3;386(6624):510-4 [9087412.001]
  • [Cites] Nat Rev Immunol. 2005 Mar;5(3):201-14 [15719024.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2594-600 [15536148.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4878-84 [15731175.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1446-51 [15973456.001]
  • [Cites] Hum Immunol. 2005 Jul;66(7):836-41 [16112031.001]
  • [Cites] Curr Top Microbiol Immunol. 2006;298:259-77 [16323418.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4370-6 [16131567.001]
  • [Cites] J Exp Med. 2006 Mar 20;203(3):633-45 [16533882.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Aug;12(8):828-36 [16864053.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Aug;12(8):876-84 [16864058.001]
  • [Cites] Bone Marrow Transplant. 2006 Sep;38(6):437-44 [16892071.001]
  • [Cites] Transplantation. 2006 Oct 27;82(8):1024-30 [17060849.001]
  • [Cites] Tissue Antigens. 2007 Apr;69 Suppl 1:42-5 [17445161.001]
  • [Cites] Tissue Antigens. 2007 Apr;69 Suppl 1:92-5 [17445176.001]
  • [Cites] Hum Immunol. 2007 May;68(5):309-23 [17462498.001]
  • [Cites] Clin Exp Immunol. 2007 Jun;148(3):520-8 [17493020.001]
  • [Cites] Blood. 2007 Jun 1;109(11):5058-61 [17317850.001]
  • [Cites] Clin Immunol. 2007 Jun;123(3):272-80 [17446137.001]
  • [Cites] Immunogenetics. 2007 Jul;59(7):525-37 [17464504.001]
  • [Cites] Blood. 2007 Jul 1;110(1):433-40 [17371948.001]
  • [Cites] J Exp Med. 2007 Nov 26;204(12):3027-36 [18025129.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4576-83 [17785583.001]
  • [Cites] Int J Immunogenet. 2008 Feb;35(1):1-8 [18093180.001]
  • [Cites] Blood. 2003 Aug 1;102(3):814-9 [12689936.001]
  • (PMID = 18945962.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518; United States / PHS HHS / / P01 111412; United States / NCI NIH HHS / CA / U24-CA76518
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / Receptors, KIR
  • [Other-IDs] NLM/ PMC2628378
  •  go-up   go-down


3. Cunningham I: A clinical review of breast involvement in acute leukemia. Leuk Lymphoma; 2006 Dec;47(12):2517-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinical review of breast involvement in acute leukemia.
  • The breast continues to be reported as a site of resistant leukemia despite current curative protocols.
  • To characterize disease behavior and potential for lengthy survival after breast relapse, a study was undertaken of 153 cases reported between 1969 and 2005.
  • Ninety percent of female patients were younger than 50 and leukemia was temporally related to pregnancy in 13.
  • Leukemia growing in the breast may follow a distinctive pattern, and prompt initiation of intensive multi-cycle treatment, assuming occult site involvement, with consideration of CSF prophylaxis, should increase the potential for disease eradication.
  • [MeSH-major] Breast Neoplasms / secondary. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Middle Aged. Pregnancy. Pregnancy Complications, Neoplastic / diagnosis. Recurrence. Remission Induction. Sarcoma, Myeloid / therapy. Stem Cell Transplantation

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17169796.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 160
  •  go-up   go-down


Advertisement
4. Matsuda K, Tanaka M, Araki S, Yanagisawa R, Yamauchi K, Koike K: Cryptic insertion into 11q23 of MLLT10 not involved in t(1;15;11;10)(p36;q11;q23;q24) in infant acute biphenotypic leukemia. Cancer Genet Cytogenet; 2009 Apr 15;190(2):113-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cryptic insertion into 11q23 of MLLT10 not involved in t(1;15;11;10)(p36;q11;q23;q24) in infant acute biphenotypic leukemia.
  • This report describes a case of infant acute biphenotypic leukemia with t(1;15;11;10)(p36;q11;q23;q24).
  • Furthermore, the level of MRD had already increased before hematologic relapse.
  • [MeSH-major] Leukemia, Biphenotypic, Acute / genetics. Transcription Factors / genetics. Translocation, Genetic / genetics

  • Genetic Alliance. consumer health - Acute Biphenotypic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19380030.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLLT10 protein, human; 0 / Transcription Factors
  •  go-up   go-down


5. Jeong SH, Han JH, Jeong SY, Kang SY, Lee HW, Choi JH, Park JS: A case of donor-derived granulocytic sarcoma after allogeneic hematopoietic stem cell transplantation. Korean J Hematol; 2010 Mar;45(1):70-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The occurrence of granulocytic sarcoma as a pattern of relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is rare.
  • In this paper, we report a rare case of acute myeloid leukemia (AML) relapsed as a granulocytic sarcoma of the donor type.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21120167.001).
  • [ISSN] 2092-9129
  • [Journal-full-title] The Korean journal of hematology
  • [ISO-abbreviation] Korean J Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2982999
  • [Keywords] NOTNLM ; AML / Allo-HSCT / Donor type / Granulocytic sarcoma
  •  go-up   go-down


6. Ogura K, Kimura F, Kobayashi S, Torikai H, Ikeda T, Sato K, Motoyoshi K: Myeloid/NK cell precursor acute leukemia lost both CD13 and CD33 at first diagnosis. Leuk Res; 2006 Jun;30(6):761-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid/NK cell precursor acute leukemia lost both CD13 and CD33 at first diagnosis.
  • Here, we report a 18-year-old man who was diagnosed with CD33- and CD13- NK cell precursor acute leukemia at first diagnosis.
  • Following a 3-year remission state, he had a relapse as a testicular tumor and CD33+ myeloid/NK cell precursor acute leukemia after allogenic BMT.
  • This case suggests that myeloid antigens are not necessary for diagnosis of myeloid/NK cell precursor acute leukemia.
  • [MeSH-major] Antigens, CD / blood. Antigens, CD13 / blood. Antigens, Differentiation, Myelomonocytic / blood. Killer Cells, Natural. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / diagnosis. Testicular Neoplasms / blood. Testicular Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140376.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD56; 0 / Antigens, CD7; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; EC 3.4.11.2 / Antigens, CD13
  •  go-up   go-down


7. Jiang NG, Chen XM, Zhu HL, Zhong L, Zeng TT, Jia YQ: [Immunophenotype characteristics and prognosis of acute leukemia patients with cross expressing lymphoid and myeloid lineage associated antigens]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec;18(6):1405-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunophenotype characteristics and prognosis of acute leukemia patients with cross expressing lymphoid and myeloid lineage associated antigens].
  • The aim of study was to investigate the immunophenotype characteristics and prognosis of acute leukemia patients with cross-expressing lymphoid and myeloid lineage-associated antigens.
  • Complete remission (CR) ratio and relapse-free survival (RFS) of patients in all groups were compared.
  • CD56(+) AML and Ly ≥ 2(+) AML have bad prognosis, while other cross-expressed lymphoid and myeloid lineage-associated antigens have no impact on prognosis of acute leukemia patients.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21176339.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD56; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; EC 3.4.11.2 / Antigens, CD13
  •  go-up   go-down


8. Furugaki K, Pokorna K, Le Pogam C, Aoki M, Reboul M, Bajzik V, Krief P, Janin A, Noguera ME, West R, Charron D, Chomienne C, Pla M, Moins-Teisserenc H, Padua RA: DNA vaccination with all-trans retinoic acid treatment induces long-term survival and elicits specific immune responses requiring CD4+ and CD8+ T-cell activation in an acute promyelocytic leukemia mouse model. Blood; 2010 Jan 21;115(3):653-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA vaccination with all-trans retinoic acid treatment induces long-term survival and elicits specific immune responses requiring CD4+ and CD8+ T-cell activation in an acute promyelocytic leukemia mouse model.
  • DNA vaccination and all-trans retinoic acid (ATRA) result in a survival advantage in a mouse model of acute promyelocytic leukemia (APL).
  • CD4(+) depletions of long-term survivors resulted in relapse and death within 3 months, thus demonstrating the need of both CD4(+) and CD8(+) subsets for the generation of DNA-driven antileukemic immune responses and underscoring a crucial role of CD4(+) cells in the maintenance of durable remissions.
  • Effectors from ATRA + DNA-treated mice were shown to secrete interferon-gamma when stimulated with either APL cells or peptides from the promyelocytic leukemia-RARalpha vaccine-derived sequences as detected by ELISpot assays.
  • [MeSH-major] CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Immunity, Cellular. Leukemia, Promyelocytic, Acute / therapy. Tretinoin / administration & dosage. Vaccines, DNA / administration & dosage

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19965687.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / Vaccines, DNA; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 5688UTC01R / Tretinoin
  •  go-up   go-down


9. León-Rodríguez E: [Hematopoietic stem cell transplantation in the myelodisplastic syndromes]. Rev Invest Clin; 2005 Mar-Apr;57(2):283-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myelodisplastic syndromes (MDS) are clonal hematopoietic disorders, characterized by ineffective hemopoiesis resulting in single or multiple lineages and a high risk of conversion to acute leukemia.
  • In the main studies the disease-free survival (DFS) were 35-43%, relapse 20 to 39% and transplantation-related mortality (TRM) 36-45%.
  • HSCT offers best results in goods prognosis MDS (refractory anemia, refractory anemia with ring sideroblasts) with DFS of 53-72% and 13% of relapse, in contrast with the advanced MDS (refractory anemia with blast in excess (AREB), AREB in transformation and secondary acute leukemia) where the DFS is about approximately 33%, the relapse 23-34% and MRT 37-60%.


10. Thomas A: Joe Burchenal and the birth of combination chemotherapy. Br J Haematol; 2006 Jun;133(5):493-503
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When Joe Burchenal started studying medicine at the University of Pennsylvania in 1934, antibiotics had not been discovered and the survival of patients diagnosed with acute leukaemia was < 4 months.
  • By the time he retired in 1983, 58% of children with acute lymphoblastic leukaemia survived 5 years with the majority being cured of their disease.
  • Success in treating lymphoid malignancies in children led him to develop treatment regimens for other more resistant cancers, and as an advocate of collaborative working he introduced multimodal therapy to tackle bulky or metastatic cancers, replacing inevitable relapse with a chance of true cure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / history. Leukemia / history
  • [MeSH-minor] Acute Disease. Anti-Infective Agents / history. Anti-Infective Agents / therapeutic use. Child. History, 20th Century. Humans. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / history. United States

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681636.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Biography; Historical Article; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Infective Agents
  • [Personal-name-as-subject] Burchenal J
  •  go-up   go-down


11. Levine MN, Pritchard KI, Bramwell VH, Shepherd LE, Tu D, Paul N, National Cancer Institute of Canada Clinical Trials Group: Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol; 2005 Aug 1;23(22):5166-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Certain anthracycline-containing adjuvant chemotherapy regimens are associated with improved relapse-free survival (RFS) and overall survival (OS) compared with the classic regimen of cyclophosphamide, methotrexate, and fluorouracil in women with early-stage breast cancer.
  • The rates of acute leukemia have not changed since the original report, whereas the rates of congestive heart failure are slightly higher but acceptable (four patients [1.1%] in the CEF group v one patient [0.3%] in the CMF group).

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16051958.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate; CMF regimen; FEC protocol
  •  go-up   go-down


12. Mody R, Li S, Dover DC, Sallan S, Leisenring W, Oeffinger KC, Yasui Y, Robison LL, Neglia JP: Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Blood; 2008 Jun 15;111(12):5515-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.
  • Survivors of childhood acute lymphoblastic leukemia (ALL) are at risk for late effects of cancer therapy.
  • Five-year ALL survivors (< 21 years at diagnosis; n = 5760 eligible, 4151 participants), diagnosed from 1970 to 1986 were compared with the general population and a sibling cohort (n = 3899).
  • Cumulative mortality of 5760 5-year survivors was 13% at 25 years from diagnosis.
  • Cumulative incidence of severe CMCs, including death, 25 years from diagnosis was 21.3% (95% CI, 18.2-24.4; 23.3% [95% CI, 19.4-27.2] and 13.4% [95% CI, 8.4-18.4] for irradiated and nonirradiated survivors, respectively).
  • Survivors who received radiation therapy as part of their treatment or had a leukemia relapse are at greatest risk for adverse outcomes.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3858-64 [16921038.001]
  • [Cites] J Clin Epidemiol. 2004 Sep;57(9):933-44 [15504636.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1303-12 [16894525.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5277-82 [17088567.001]
  • [Cites] Pediatr Blood Cancer. 2007 Apr;48(4):460-7 [16767717.001]
  • [Cites] J Pediatr. 2007 Apr;150(4):370-5, 375.e1 [17382112.001]
  • [Cites] Pediatr Blood Cancer. 2007 Jul;49(1):65-73 [16628558.001]
  • [Cites] Pediatr Blood Cancer. 2007 Jul;49(1):47-51 [16755550.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1356-63 [17627001.001]
  • [Cites] Am J Obstet Gynecol. 2002 Oct;187(4):1070-80 [12389007.001]
  • [Cites] Cancer. 2002 Dec 1;95(11):2431-41 [12436452.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1687-95 [10738228.001]
  • [Cites] Blood. 2000 May 1;95(9):2770-5 [10779419.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3163-72 [11432882.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3173-81 [11432883.001]
  • [Cites] Cancer. 2001 Oct 1;92(7):1977-83 [11745273.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4257-64 [12036851.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3136-41 [12107213.001]
  • [Cites] Cancer. 1986 Jul 15;58(2 Suppl):598-602 [3719551.001]
  • [Cites] N Engl J Med. 1987 Sep 3;317(10):588-93 [3475572.001]
  • [Cites] JAMA. 1989 Nov 17;262(19):2693-9 [2810602.001]
  • [Cites] Cancer. 1991 Jan 1;67(1):206-13 [1985719.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1990 Winter;12(4):454-61 [2285126.001]
  • [Cites] Acta Paediatr Scand. 1991 Dec;80(12):1220-8 [1785295.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1397-406 [1517782.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1994 May;16(2):143-52 [8166367.001]
  • [Cites] JAMA. 1994 Nov 9;272(18):1427-32 [7933424.001]
  • [Cites] Child Care Health Dev. 1994 Sep-Oct;20(5):309-22 [7988001.001]
  • [Cites] J Dev Behav Pediatr. 1994 Oct;15(5):353-66 [7868704.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2186-95 [7697611.001]
  • [Cites] N Engl J Med. 1995 Jun 15;332(24):1618-30 [7753142.001]
  • [Cites] Arch Dis Child. 1995 Aug;73(2):136-40 [7574857.001]
  • [Cites] J Child Psychol Psychiatry. 1996 Jul;37(5):597-607 [8807440.001]
  • [Cites] Oncology (Williston Park). 1997 Feb;11(2):259-64; discussion 264-5 [9057179.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2205-13 [9196132.001]
  • [Cites] Pediatr Clin North Am. 1997 Aug;44(4):1021-42 [9286298.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2848-53 [9704738.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):605-15 [9718381.001]
  • [Cites] Eur J Cancer. 1998 Apr;34(5):694-8 [9713276.001]
  • [Cites] Curr Probl Pediatr. 1998 Oct;28(9):273-97 [9794096.001]
  • [Cites] Stat Med. 1999 Mar 30;18(6):695-706 [10204198.001]
  • [Cites] Br J Cancer. 2004 Nov 29;91(11):1905-10 [15534607.001]
  • [Cites] Lancet. 2005 Jun 11-17;365(9476):2014-23 [15950715.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9187-97 [16361621.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2536-43 [16735706.001]
  • [Cites] J Natl Cancer Inst. 2006 Jul 5;98(13):890-6 [16818852.001]
  • [Cites] Turk J Pediatr. 2006 Apr-Jun;48(2):101-4 [16848106.001]
  • [Cites] Acta Paediatr. 2006 Aug;95(8):922-8 [16882563.001]
  • [Cites] Eur J Cancer. 2003 Feb;39(3):359-65 [12565989.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1115-26 [12569614.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1359-65 [12663727.001]
  • [Cites] Cancer. 2003 May 15;97(10):2554-64 [12733155.001]
  • [Cites] N Engl J Med. 2003 Aug 14;349(7):640-9 [12917300.001]
  • [Cites] JAMA. 2003 Sep 24;290(12):1583-92 [14506117.001]
  • [Cites] Ann Intern Med. 2004 Oct 19;141(8):590-7 [15492338.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Sep;91(9):3494-8 [16822820.001]
  • (PMID = 18334672.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / PHS HHS / / U24 55727; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2424150
  •  go-up   go-down


13. Sedlacek P, Mejstrikova E, Formankova R, Keslova P, Dobrovolna M, Vrana M, Stary J: Allo-SCT in children with high-risk leukemia using unmanipulated grafts from alternative donors. Bone Marrow Transplant; 2008 Oct;42 Suppl 2:S10-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allo-SCT in children with high-risk leukemia using unmanipulated grafts from alternative donors.
  • Allogeneic HSCT is a curative treatment for high-risk leukemia.
  • Here we evaluate the outcomes of 87 consecutive patients with leukemia transplanted with unmanipulated graft from matched or partially mismatched UD or cord blood (CB) at our institution between January 2001 and December 2007.
  • Within the median follow-up of 30 months, the acute GVHD grade II was diagnosed in 70.9% patients; grades III-IV only in 4.6%.
  • Fourteen patients (16.1%) died as a consequence of post-transplant leukemia relapse.
  • We conclude that the prognosis of patients transplanted for leukemia using unmanipulated grafts from HLA-matched or partially mismatched UD or CB is comparable and satisfactory.
  • TRM and relapse rate are lower than in the earlier period.
  • [MeSH-major] Donor Selection. Hematopoietic Stem Cell Transplantation. Leukemia / mortality. Leukemia / therapy. Living Donors
  • [MeSH-minor] Acute Disease. Child. Child, Preschool. Chronic Disease. Disease-Free Survival. Europe. Female. Follow-Up Studies. Graft vs Host Disease / mortality. Graft vs Host Disease / therapy. Histocompatibility Testing. Humans. Male. Recurrence. Risk Factors. Survival Rate. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18978735.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 14
  •  go-up   go-down


14. Heidel F, Lipka DB, Mirea FK, Mahboobi S, Grundler R, Kancha RK, Duyster J, Naumann M, Huber C, Böhmer FD, Fischer T: Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro. Br J Haematol; 2009 Mar;144(6):865-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inhibition of the mutated fms-like tyrosine kinase 3 (FLT3) receptor tyrosine kinase is a promising therapeutic strategy in acute myeloid leukaemia (AML).
  • This observation may have an increasing impact on the duration of response and relapse rates in upcoming clinical trials employing FLT3-TKI.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Indoles / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Staurosporine / analogs & derivatives. Tandem Repeat Sequences. fms-Like Tyrosine Kinase 3 / genetics


15. Hirano N, Butler MO, Xia Z, Berezovskaya A, Murray AP, Ansén S, Kojima S, Nadler LM: Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia. Blood; 2006 Oct 15;108(8):2662-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia.
  • Juvenile myelomonocytic leukemia (JMML) is a rare clonal myeloproliferative disorder.
  • Although allogeneic stem cell transplantation can induce long-term remissions, relapse rates remain high and innovative approaches are needed.

  • Genetic Alliance. consumer health - Juvenile Myelomonocytic Leukemia (JMML).
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 1999 Dec 1;163(11):5851-9 [10570269.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1528-36 [16239433.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4796-801 [10759561.001]
  • [Cites] Eur J Immunol. 2001 Sep;31(9):2642-51 [11536162.001]
  • [Cites] Leukemia. 2002 Apr;16(4):645-9 [11960345.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12275-80 [12218171.001]
  • [Cites] Science. 2002 Oct 25;298(5594):850-4 [12242449.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1713-4 [12393482.001]
  • [Cites] Leukemia. 2003 Feb;17(2):277-82 [12592323.001]
  • [Cites] Cancer Immun. 2002 Oct 14;2:14 [12747759.001]
  • [Cites] Nat Rev Immunol. 2003 Aug;3(8):630-41 [12974478.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4567-75 [12947009.001]
  • [Cites] Bone Marrow Transplant. 2004 Jan;33(1):113-5 [14704663.001]
  • [Cites] Blood. 2004 Feb 1;103(3):767-76 [12958064.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):828-39 [14871958.001]
  • [Cites] J Clin Invest. 2004 Jun;113(11):1515-25 [15173875.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):2967-75 [16707591.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4688-98 [15269141.001]
  • [Cites] Nat Med. 2004 Sep;10(9):909-15 [15340416.001]
  • [Cites] Blood. 1974 Mar;43(3):341-50 [4521369.001]
  • [Cites] Br J Haematol. 1986 Nov;64(3):539-46 [2947609.001]
  • [Cites] Blood. 1987 Mar;69(3):975-6 [3469003.001]
  • [Cites] J Immunol. 1993 Oct 1;151(7):3719-27 [7690811.001]
  • [Cites] J Immunol. 1994 Jan 1;152(1):163-75 [8254189.001]
  • [Cites] Br J Haematol. 1995 Jun;90(2):353-7 [7794756.001]
  • [Cites] Blood. 1995 Jul 1;86(1):323-8 [7795240.001]
  • [Cites] Leukemia. 1996 Jul;10(7):1168-76 [8683998.001]
  • [Cites] Blood. 1997 May 15;89(10):3534-43 [9160658.001]
  • [Cites] Blood. 1997 Jul 15;90(2):479-88 [9226148.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10850-5 [9380723.001]
  • [Cites] Eur J Immunol. 1998 Dec;28(12):4029-36 [9862339.001]
  • [Cites] Immunity. 1999 Jun;10(6):673-9 [10403642.001]
  • [Cites] Blood. 2005 Jan 1;105(1):410-9 [15353481.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2346-57 [15800326.001]
  • [Cites] Leukemia. 2005 Jun;19(6):971-7 [15800672.001]
  • [Cites] Cancer Immunol Immunother. 2005 Jul;54(7):703-12 [15726360.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):51-7 [15982344.001]
  • [Cites] Nat Biotechnol. 2005 Sep;23(9):1147-57 [16151408.001]
  • [Cites] Am J Hematol. 2000 Apr;63(4):212-22 [10706766.001]
  • (PMID = 16778141.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 87720; United States / NCI NIH HHS / CA / CA 92625-04; United States / NHLBI NIH HHS / HL / HL 54785-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Epitopes; 0 / HLA-A2 Antigen; 9004-22-2 / Globins
  • [Other-IDs] NLM/ PMC1895581
  •  go-up   go-down


16. Shook D, Coustan-Smith E, Ribeiro RC, Rubnitz JE, Campana D: Minimal residual disease quantitation in acute myeloid leukemia. Clin Lymphoma Myeloma; 2009;9 Suppl 3:S281-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease quantitation in acute myeloid leukemia.
  • The prognosis for patients with acute myeloid leukemia (AML) is heterogeneous.
  • A minority of patients have clinical and biologic features associated with a very high risk of relapse.
  • For the remaining patients, no clear prognostic factors can be identified at diagnosis.
  • Other clinically informative uses of MRD testing include the detection of early relapse and the evaluation of the efficacy of new antileukemic agents.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Oct 1;100(7):2393-8 [12239147.001]
  • [Cites] Cytometry B Clin Cytom. 2009 Mar;76(2):91-101 [18727068.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1013-34 [12764363.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1130-6 [12764380.001]
  • [Cites] Br J Haematol. 2003 Jun;121(6):823-38 [12786792.001]
  • [Cites] Blood. 2003 Jul 15;102(2):773-4; author reply 774 [12835231.001]
  • [Cites] Br J Haematol. 2003 Oct;123(2):243-52 [14531905.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2318-57 [14562125.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1441-4 [15201851.001]
  • [Cites] Blood. 1990 Jul 1;76(1):163-71 [1973061.001]
  • [Cites] Anal Cell Pathol. 1990 Jul;2(4):229-40 [1703434.001]
  • [Cites] J Clin Pathol. 1996 Jan;49(1):15-8 [8666678.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1217-25 [9242555.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2465-70 [9310499.001]
  • [Cites] Leukemia. 1998 Sep;12(9):1482-9 [9737700.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3078-85 [15284114.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:98-117 [15561679.001]
  • [Cites] Leukemia. 2005 Mar;19(3):367-72 [15674426.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1416-23 [15920493.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):146-55 [16491074.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1507-15 [16575000.001]
  • [Cites] Blood. 2000 Feb 1;95(3):815-9 [10648391.001]
  • [Cites] Leukemia. 2000 Mar;14(3):522-4 [10720156.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3948-52 [11090082.001]
  • [Cites] Blood. 2001 Jan 1;97(1):89-94 [11133746.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3574-80 [11369653.001]
  • [Cites] Leukemia. 2001 Jul;15(7):1033-7 [11455970.001]
  • [Cites] Leukemia. 2001 Jul;15(7):1072-80 [11455976.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1746-51 [11535507.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1752-9 [11535508.001]
  • [Cites] Blood. 2002 Jan 15;99(2):443-9 [11781223.001]
  • [Cites] Leukemia. 2002 Mar;16(3):368-75 [11896540.001]
  • [Cites] Lancet Oncol. 2001 Jul;2(7):409-17 [11905735.001]
  • [Cites] Leukemia. 2002 Jun;16(6):1176-81 [12040450.001]
  • [Cites] Lancet. 2002 Jul 13;360(9327):160-2 [12126839.001]
  • [Cites] Br J Haematol. 2002 Aug;118(2):411-8 [12139724.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2387-92 [12239146.001]
  • [Cites] Leukemia. 2006 Jan;20(1):87-94 [16281071.001]
  • [Cites] Leukemia. 2006 Jun;20(6):1103-8 [16541144.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):273-82 [16848770.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3686-92 [16877738.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:156-61, 514 [17124055.001]
  • [Cites] Cancer. 2007 Nov 1;110(9):1900-10 [17786921.001]
  • [Cites] Cancer. 2008 Jan 1;112(1):4-16 [18000811.001]
  • [Cites] Blood. 2008 May 15;111(10):4930-3 [18305215.001]
  • [Cites] Clin Chim Acta. 2008 Sep;395(1-2):120-3 [18590714.001]
  • [Cites] Semin Oncol. 2008 Aug;35(4):388-400 [18692689.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4944-51 [18606980.001]
  • [Cites] Cytometry A. 2008 Dec;73A(12):1141-50 [18836994.001]
  • [Cites] Blood. 2003 May 1;101(9):3398-406 [12506020.001]
  • (PMID = 19778853.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA115422-04; United States / NCI NIH HHS / CA / T32 CA070089; United States / NCI NIH HHS / CA / CA115422; United States / NCI NIH HHS / CA / CA70089; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / R01 CA115422-04; United States / NCI NIH HHS / CA / R01 CA115422
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  • [Number-of-references] 51
  • [Other-IDs] NLM/ NIHMS160693; NLM/ PMC2785493
  •  go-up   go-down


17. Langebrake C, Brinkmann I, Teigler-Schlegel A, Creutzig U, Griesinger F, Puhlmann U, Reinhardt D: Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring. Cytometry B Clin Cytom; 2005 Jan;63(1):1-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring.
  • BACKGROUND: Determination of antigen expression patterns is, in addition to morphologic analysis, essential to the diagnosis of acute myeloid leukemia (AML).
  • The present study was performed to determine (a) the degree of changes in immunophenotype and their consequences on the monitoring of minimal residual disease (MRD) in childhood AML and (b) whether certain clusters of changes in antigen expression patterns exist between diagnosis and relapse.
  • METHODS: Bone marrow specimens of 48 children enrolled in the German AML-BFM-93/98 (Acute Myeloid Leukemia-Berlin-Frankfurt-Munster) studies were analyzed immunologically, morphologically, and genetically at diagnosis and at first relapse.
  • RESULTS: The immunophenotypes by flow cytometry differed by at least one antigen between samples at presentation and relapse in 42 of 48 children (88%).
  • More children displayed an immature phenotype at relapse (43 of 47, 91.5%, vs. 37 of 48, 77%; P = 0.05) with expression of CD34 and/or CD117.
  • [MeSH-major] Antigens, Neoplasm / immunology. Immunophenotyping / methods. Leukemia, Myeloid / diagnosis. Neoplasm, Residual / diagnosis
  • [MeSH-minor] Acute Disease. Adolescent. Biomarkers, Tumor / genetics. Biomarkers, Tumor / immunology. Bone Marrow / immunology. Bone Marrow / pathology. Child. Child, Preschool. Clone Cells. Flow Cytometry. Humans. Infant. Karyotyping. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15624201.001).
  • [ISSN] 1552-4949
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  •  go-up   go-down


18. Lee SE, Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, Min CK, Lee S, Cho SG, Kim DW, Lee JW, Park CW, Kim CC: Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities. Int J Hematol; 2010 Sep;92(2):342-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities.
  • At a median follow-up of 18 months (range 4-40) for survivors, the estimated 2-year rates of overall survival, event-free survival, transplantation-related mortality, and relapse were 66, 63, 26, and 16%, respectively.
  • The incidence of acute (grades II-IV) and chronic GVHD by NIH consensus criteria was 34.4 and 62.5%.
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Antineoplastic Agents. Antineoplastic Agents, Alkylating. Comorbidity. Female. Humans. Leukemia, Myeloid, Acute. Male. Middle Aged. Survival Analysis. Transplantation Conditioning / methods. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Blood Marrow Transplant. 2010 Sep;16(9):1315-23 [20353831.001]
  • [Cites] Blood. 2006 May 1;107(9):3463-8 [16384925.001]
  • [Cites] Br J Haematol. 2010 Apr;149(1):101-10 [20067562.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Jun;15(6):704-17 [19450755.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):444-53 [16344316.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 May;12(5):573-84 [16635793.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4606-13 [17873123.001]
  • [Cites] Bone Marrow Transplant. 2007 Feb;39(4):193-9 [17220905.001]
  • [Cites] Leukemia. 2007 Jul;21(7):1357-62 [17508002.001]
  • [Cites] Am J Hematol. 2010 Apr;85(4):243-8 [20162540.001]
  • [Cites] Int J Hematol. 2007 Apr;85(3):256-63 [17483064.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56 [16338616.001]
  • [Cites] Biol Blood Marrow Transplant. 2002;8(9):468-76 [12374451.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:384-9 [16304408.001]
  • [Cites] Bone Marrow Transplant. 2005 Oct;36(8):667-74 [16113674.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2072-7 [12357359.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2304-12 [16193083.001]
  • [Cites] Bone Marrow Transplant. 2008 Mar;41(5):415-23 [18209726.001]
  • [Cites] Curr Opin Oncol. 2007 Nov;19(6):660-6 [17906468.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Jul;13(7):814-21 [17580259.001]
  • [Cites] Blood. 2001 Nov 15;98(10):2942-7 [11698275.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):544-51 [17141976.001]
  • (PMID = 20694843.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine
  •  go-up   go-down


19. Karp JE, Smith BD, Levis MJ, Gore SD, Greer J, Hattenburg C, Briel J, Jones RJ, Wright JJ, Colevas AD: Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res; 2007 Aug 1;13(15 Pt 1):4467-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
  • In a phase I study of flavopiridol followed by 1-beta-d-arabinofuranosylcytosine (ara-C) and mitoxantrone, overall response rate for adults with relapsed and refractory acute myelogenous leukemias (AML) was 31%.
  • Complete remissions (CR) were achieved in 12 of 15 (75%) newly diagnosed secondary AML, 18 of 24 (75%) first relapse after short CR (median CR, 9 months, including prior allotransplant), and 2 of 13 (15%) primary refractory but 0 of 10 multiply refractory AML.
  • This timed sequential regimen induces durable CRs in a significant proportion of adults with newly diagnosed secondary AML (including complex cytogenetics) and adults with AML in first relapse after short first CR.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671131.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01-RR0052; United States / NCI NIH HHS / CA / U01 CA70095
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Piperidines; 04079A1RDZ / Cytarabine; 45AD6X575G / alvocidib; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


20. Viana MB, Vilela MI: Height deficit during and many years after treatment for acute lymphoblastic leukemia in children: a review. Pediatr Blood Cancer; 2008 Feb;50(2 Suppl):509-16; discussion 517
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Height deficit during and many years after treatment for acute lymphoblastic leukemia in children: a review.
  • There are conflicting data on the incidence and severity of height deficits in children with acute lymphoblastic leukemia (ALL).
  • ALL relapse in GH-treated children is not more common than in those not treated with GH.
  • [MeSH-major] Body Height. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18064646.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-72-6 / Growth Hormone
  • [Number-of-references] 25
  •  go-up   go-down


21. Ning H, Yang F, Jiang M, Hu L, Feng K, Zhang J, Yu Z, Li B, Xu C, Li Y, Wang J, Hu J, Lou X, Chen H: The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia; 2008 Mar;22(3):593-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Grades II-IV acute graft-versus-host disease (GVHD) was observed respectively, in one (11.1%) and eight (53.3%) evaluable patients.
  • Thus cotransplantation of MSCs and HSCs may prevent GVHD, but the relapse rate is obviously higher than the control group.
  • [MeSH-minor] Adolescent. Adult. Female. Graft Survival. Graft vs Leukemia Effect. Humans. Immunosuppression. Immunosuppressive Agents / therapeutic use. Male. Middle Aged. Pilot Projects. Recurrence

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leukemia. 2008 Mar;22(3):463-5 [18335000.001]
  • [CommentIn] Leukemia. 2009 Jan;23(1):178; author reply 179-80 [18548101.001]
  • [CommentIn] Leukemia. 2008 Dec;22(12):2273 [18528424.001]
  • (PMID = 18185520.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


22. Tadesse MG, Ibrahim JG, Gentleman R, Chiaretti S, Ritz J, Foa R: Bayesian error-in-variable survival model for the analysis of GeneChip arrays. Biometrics; 2005 Jun;61(2):488-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a Bayesian error-in-variable model for the analysis of microarray data from a clinical study of patients with acute lymphoblastic leukemia.
  • This is a question of great practical interest since relapse is a major concern in the treatment of this disease.
  • [MeSH-minor] Bayes Theorem. Biometry. Gene Expression Profiling. Humans. Models, Statistical. Phenotype. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proportional Hazards Models. RNA, Messenger / metabolism. Regression Analysis. Remission Induction. Sequence Analysis, DNA. Software

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16011696.001).
  • [ISSN] 0006-341X
  • [Journal-full-title] Biometrics
  • [ISO-abbreviation] Biometrics
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA66996; United States / NCI NIH HHS / CA / CA70101; United States / NCI NIH HHS / CA / CA74015; United States / NCI NIH HHS / CA / CA90301
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger
  •  go-up   go-down


23. Laport GG, Alvarnas JC, Palmer JM, Snyder DS, Slovak ML, Cherry AM, Wong RM, Negrin RS, Blume KG, Forman SJ: Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. Blood; 2008 Aug 1;112(3):903-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen.
  • Allogeneic hematopoietic cell transplantation (HCT) is the only known curative modality for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL).
  • There was no significant difference in relapse incidence (28% vs 41%, P = .28), but nonrelapse mortality was significantly higher in the beyond CR1 patients, (31% vs 54%, P = .03, respectively).
  • By univariate analysis, factors affecting event-free and overall survival were white blood cell count at diagnosis (< 30 x 10(9)/L vs > 30 x 10(9)/L) and disease status (CR1 vs > CR1).
  • The median time to relapse for CR1 and for beyond CR1 patients was 12 months and 9 months, respectively.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2005 Nov;36(10):867-72 [16113659.001]
  • [Cites] IARC Sci Publ. 1987;(82):1-406 [3329634.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Apr;12(4):438-53 [16545728.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2791-3 [17119111.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2563-72 [18156492.001]
  • [Cites] Leukemia. 1999 Dec;13(12):2053-8 [10602428.001]
  • [Cites] Leuk Lymphoma. 2000 Jan;36(3-4):263-73 [10674898.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3702-9 [10845900.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1038-42 [11287973.001]
  • [Cites] Blood. 2002 Aug 1;100(3):761-7 [12130483.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1965-71 [12200353.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2357-66 [12239143.001]
  • [Cites] Semin Hematol. 2002 Oct;39(4 Suppl 3):32-7 [12447850.001]
  • [Cites] Br J Haematol. 2003 Jan;120(1):145-53 [12492591.001]
  • [Cites] Bone Marrow Transplant. 2003 May;31(10):909-18 [12748668.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4396-407 [14551133.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1981 Aug;7(8):1109-15 [7028698.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1983 Nov;9(11):1607-11 [6358154.001]
  • [Cites] Blood. 1992 Jun 1;79(11):3067-70 [1586748.001]
  • [Cites] Blood. 1993 Nov 1;82(9):2920-8 [8219241.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1672-9 [8068956.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3135-42 [8605327.001]
  • [Cites] Blood. 1997 Aug 15;90(4):1410-4 [9269758.001]
  • [Cites] Biol Blood Marrow Transplant. 1997 Dec;3(6):324-30 [9502300.001]
  • [Cites] Blood. 2005 May 1;105(9):3449-57 [15657178.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1509-16 [16034462.001]
  • [Cites] Blood. 1987 Apr;69(4):1015-20 [3548841.001]
  • [Cites] Blood. 1987 Aug;70(2):587-8 [3300815.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • (PMID = 18519812.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA030206; United States / NCI NIH HHS / CA / P01 CA049605; United States / NCI NIH HHS / CA / P01-CA 30206; United States / NCI NIH HHS / CA / P01-CA 49605
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 6PLQ3CP4P3 / Etoposide; 8A1O1M485B / Imatinib Mesylate
  • [Other-IDs] NLM/ PMC2481551
  •  go-up   go-down


24. Sun JF, Han XP, Zhao DD, Wang FF, Jin HJ, Gao CJ, DA WM, Yu L: [Application of chimerism analysis to allogeneic hematopoietic stem cell transplantation by STR-PCR]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr;15(2):337-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 14 patients with 100% donor chimerism (DC) had stable engraftment and they still survive in free leukemia.
  • Decrease of donor chimerism appeared prior to graft rejection and disease relapse.
  • It is concluded that dynamic monitoring donor chimerism by STR-PCR in combination with all auto-capillary electrophoresis is a valuable tool for predicting graft rejection, disease relapse and occurrence of GVHD, and provides a basis for early clinical intervention in the patients received allo-HSCT.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493343.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


25. Palle J, Frost BM, Petersson C, Hasle H, Hellebostad M, Kanerva J, Schmiegelow K, Lönnerholm G, Nordic Society for Paediatric Haematology and Oncology: Thioguanine pharmacokinetics in induction therapy of children with acute myeloid leukemia. Anticancer Drugs; 2009 Jan;20(1):7-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thioguanine pharmacokinetics in induction therapy of children with acute myeloid leukemia.
  • We studied the pharmacokinetics of 6-thioguanine (6TG) in 50 children treated for newly diagnosed acute myeloid leukemia, four of them with Down syndrome (DS).
  • Children with high TGN concentration tended to have longer treatment interval to the next course, but we found no correlation with our predefined parameters for clinical response, that is, remission and relapse rate.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacokinetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Down Syndrome / complications. Leukemia, Myeloid, Acute / drug therapy. Thioguanine / pharmacokinetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Anticancer Drugs. 2010 Jan;21(1):130. Josefine, Palle [corrected to Palle, Josefine]; Britt-Marie, Frost [corrected to Frost, Britt-Marie]; Curt, Petersson [corrected to Petersson, Curt]; Henrik, Hasle [corrected to Hasle, Henrik]; Marit, Hellebostad [corrected to Hellebostad, Marit]; Jukka, Kanerva [corrected to Kanerva, Jukka]; Kjeld, Schmiegelow [corrected to Schmiegelow, Kjeld]; Gudmar, Lönnerholm [corrected to Lönnerholm, Gudmar]
  • (PMID = 19342996.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Guanine Nucleotides; 0 / Thionucleotides; 04079A1RDZ / Cytarabine; 15867-02-4 / 6-thioguanylic acid; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; FTK8U1GZNX / Thioguanine
  •  go-up   go-down


26. Lin PC, Chang TT, Lin SR, Chiou SS, Jang RC, Sheen JM: TEL/AML1 fusion gene in childhood acute lymphoblastic leukemia in southern Taiwan. Kaohsiung J Med Sci; 2008 Jun;24(6):289-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TEL/AML1 fusion gene in childhood acute lymphoblastic leukemia in southern Taiwan.
  • Chromosomal abnormalities are found in 80-90% of childhood cases of acute lymphoblastic leukemia (ALL).
  • Leukemia-specific chromosome aberrations not only have prognostic value, but also provide important clues for further investigation into leukogenesis, leukemic cell transformation, and proliferation.
  • This study used reverse transcriptase-polymerase chain reaction techniques to detect transcripts of the leukemia-specific chromosome fusion gene, TEL/AML1, and to monitor the expression levels of the TEL-AML1 fusion transcript in ALL patients at sequential intervals during their treatment course.
  • Twenty-five ALL patients were enrolled, including 20 who were newly diagnosed and five in relapse.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / biosynthesis. Core Binding Factor Alpha 2 Subunit / genetics. Gene Expression Regulation, Leukemic. Oncogene Proteins, Fusion / biosynthesis. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18635414.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


27. Kobayashi R, Sato T, Nakajima M, Kaneda M, Iguchi A, Yoshida M: [Cord blood transplantation for acute lymphoblastic leukemia in children: analysis at a single institution]. Rinsho Ketsueki; 2008 Dec;49(12):1593-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cord blood transplantation for acute lymphoblastic leukemia in children: analysis at a single institution].
  • We examined the result of cord blood transplantation (CBT) for acute lymphoblastic leukemia (ALL) in children.
  • The relapse rate in the U-CBT group was equal to that in the R-BMT/PBSCT group, and the transplant-related mortality of U-CBT was 0%.
  • [MeSH-major] Cord Blood Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19110519.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


28. Imataki O, Ohnishi H, Yamaoka G, Arai T, Kitanaka A, Kubota Y, Kushida Y, Ishida T, Tanaka T: Lineage switch from precursor B cell acute lymphoblastic leukemia to acute monocytic leukemia at relapse. Int J Clin Oncol; 2010 Feb;15(1):112-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lineage switch from precursor B cell acute lymphoblastic leukemia to acute monocytic leukemia at relapse.
  • A lineage switch in leukemia, in which the leukemic cell lineage at onset converts to another lineage at a later time, is an uncommon type of hybrid (mixed) leukemia regarded as a variation of bilineage leukemia.
  • We present a case of a 60-year-old female diagnosed with precursor B cell acute lymphoblastic leukemia (ALL), whose markers in flow cytometry shifted from their original status of CD19+, 22+, 79a+, 13+, HLA-DR+, and TdT+.
  • This phenotypical conversion from B-ALL to hybrid leukemia featuring monocytoid characteristics is known as a lineage switch.
  • [MeSH-major] Leukemia, Biphenotypic, Acute / pathology. Leukemia, Monocytic, Acute / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1995 Dec;9(12):2023-6 [8609712.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):311-21 [15803157.001]
  • [Cites] Br J Haematol. 1987 Mar;65(3):261-4 [3552021.001]
  • [Cites] Leuk Lymphoma. 2005 Aug;46(8):1223-7 [16085566.001]
  • [Cites] Blood. 1984 Sep;64(3):701-6 [6590097.001]
  • [Cites] Blood. 1989 Nov 1;74(6):2088-95 [2553159.001]
  • [Cites] Haematologica. 2004 Aug;89(8):ECR28 [15339697.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Jan 15;164(2):118-21 [16434313.001]
  • [Cites] Am J Hematol. 2000 Sep;65(1):72-4 [10936868.001]
  • [Cites] Clin Haematol. 1986 Aug;15(3):811-27 [3536242.001]
  • [Cites] Blood Rev. 1988 Mar;2(1):9-15 [3289656.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Jul 15;168(2):146-9 [16843104.001]
  • [Cites] Br J Haematol. 1993 May;84(1):49-60 [7687860.001]
  • (PMID = 20066454.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


29. Imai K, Akiyama H: [Acute lymphoblastic leukemia (ALL)]. Gan To Kagaku Ryoho; 2007 Dec;34(13):2180-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute lymphoblastic leukemia (ALL)].
  • In the past few decades, the results of treatment for childhood acute lymphoblastic leukemia (ALL) have achieved about 80% long-term disease-free survival (DFS).
  • Although the complete remission (CR) rate of adult ALL has also improved from 70 to 90%, 5-year overall survival (OS) remains only about 30% because of the high incidence of relapse.
  • At the same time, resistance to imatinib, resulting in relapse, is also reported.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18079617.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 22
  •  go-up   go-down


30. Seggewiss R, Einsele H: Hematopoietic growth factors including keratinocyte growth factor in allogeneic and autologous stem cell transplantation. Semin Hematol; 2007 Jul;44(3):203-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of hematopoietic stem cell transplantation (HSCT) is to cure patients of malignancies, autoimmune diseases, and immunodeficiency disorders by redirecting the immune system: the often described graft-versus-leukemia (GVL) or graft-versus-tumor (GVT) effects.
  • Unfortunately, fulfillment of this goal is often hampered by relapse of the underlying disease, graft-versus-host disease (GVHD), or severe opportunistic infections, which account for the majority of post-transplantation deaths.
  • Moreover, studies of long-term survivors of transplantation indicate an accelerated immune aging due to the transplantation procedure itself, preceding chemo- or radiotherapy, and acute and chronic GVHD.

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17631184.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hematopoietic Cell Growth Factors; 126469-10-1 / Fibroblast Growth Factor 7; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  • [Number-of-references] 93
  •  go-up   go-down


31. Nakasone H, Izutsu K, Wakita S, Yamaguchi H, Muramatsu-Kida M, Usuki K: Autologous stem cell transplantation with PCR-negative graft would be associated with a favorable outcome in core-binding factor acute myeloid leukemia. Biol Blood Marrow Transplant; 2008 Nov;14(11):1262-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation with PCR-negative graft would be associated with a favorable outcome in core-binding factor acute myeloid leukemia.
  • Although core-binding factor acute myeloid leukemia (CBF-AML) is generally considered to be a low-risk form of AML, the survival rate is still 50% to 60%.
  • Between 1997 and 2006, 18 patients aged<60 years were referred under a diagnosis of CBF-AML.
  • Although 1 case of myelodysplastic syndrome occurred, there was no case of relapse.
  • [MeSH-major] Core Binding Factors. Leukemia, Myeloid, Acute / therapy. Monitoring, Physiologic. Peripheral Blood Stem Cell Transplantation. Polymerase Chain Reaction


32. García-Fuster MJ, Ramos-Miguel A, Rivero G, La Harpe R, Meana JJ, García-Sevilla JA: Regulation of the extrinsic and intrinsic apoptotic pathways in the prefrontal cortex of short- and long-term human opiate abusers. Neuroscience; 2008 Nov 11;157(1):105-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Opiate addiction is a chronic medical disorder characterized by drug tolerance and dependence, behavioral sensitization, vulnerability to compulsive relapse, and high mortality.
  • In the intrinsic pathway, the pro-apoptotic mitochondrial proteins Bax (Bcl-2-associated X protein) and AIF (apoptosis-inducing factor) remained unchanged, but cytochrome c was decreased (all addicts: 25%; ST: 31%; LT: 20%) and anti-apoptotic B-cell leukemia 2 (Bcl-2) increased in LT addicts (24%).
  • These neurochemical adaptations could play a major role in the development of opiate tolerance, sensitization and relapse in human addicts.
  • [MeSH-minor] Acute Disease. Adult. Aging / metabolism. Apoptosis Regulatory Proteins / metabolism. Blotting, Western. Brain Chemistry. Chronic Disease. Female. Hair / chemistry. Humans. Male. Middle Aged. Narcotics / analysis. Narcotics / blood. Neuronal Plasticity / physiology. Sex Characteristics. Synapses / physiology. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18834930.001).
  • [ISSN] 0306-4522
  • [Journal-full-title] Neuroscience
  • [ISO-abbreviation] Neuroscience
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Narcotics
  •  go-up   go-down


33. Jekarl DW, Kim M, Lim J, Kim Y, Han K, Lee AW, Kim HJ, Min WS: CD56 antigen expression and hemophagocytosis of leukemic cells in acute myeloid leukemia with t(16;21)(p11;q22). Int J Hematol; 2010 Sep;92(2):306-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD56 antigen expression and hemophagocytosis of leukemic cells in acute myeloid leukemia with t(16;21)(p11;q22).
  • The translocation t(16;21)(p11;q22) is rare, occurs with an incidence of 1%, in acute myeloid leukemia (AML), forming TLS/FUS-ERG fusion transcript, and it is known to cause the hemophagocytosis and vacuolation of leukemic cells.
  • AML with t(16;21) showed a very low rate of complete remission after induction chemotherapy (8.3%), and high relapse (75%) and mortality (75%) rates.
  • [MeSH-major] Antigens, CD56 / analysis. Cytophagocytosis. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / pathology. Translocation, Genetic

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Haematol. 1978 Jan;20(1):85-8 [272729.001]
  • [Cites] Leukemia. 2009 Jan;23(1):78-84 [18830253.001]
  • [Cites] Nat Genet. 1999 Oct;23(2):166-75 [10508512.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1192-9 [9242552.001]
  • [Cites] Haematologica. 2002 Mar;87(3):250-6 [11869936.001]
  • [Cites] Int J Hematol. 1991 Oct;54(5):395-403 [1721853.001]
  • [Cites] Scand J Haematol. 1973;11(3):253-6 [4128872.001]
  • [Cites] Leukemia. 2008 Aug;22(8):1567-75 [18528428.001]
  • [Cites] Br J Haematol. 1999 Jun;105(3):711-9 [10354136.001]
  • [Cites] Leukemia. 2001 Aug;15(8):1161-4 [11480556.001]
  • [Cites] EMBO J. 2007 Feb 21;26(4):1163-75 [17290219.001]
  • [Cites] West J Med. 1977 Feb;126(2):139-41 [265650.001]
  • [Cites] Blood. 1997 Aug 15;90(4):1643-8 [9269784.001]
  • [Cites] Blood. 2009 Dec 17;114(26):5352-61 [19808697.001]
  • [Cites] Leuk Lymphoma. 2004 May;45(5):1061-4 [15291368.001]
  • [Cites] Leukemia. 2003 Jan;17(1):9-16 [12529654.001]
  • [Cites] Cancer Genet Cytogenet. 2009 Oct 15;194(2):111-8 [19781443.001]
  • [Cites] Blood. 1977 Jan;49(1):19-27 [299732.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1308-16 [17485549.001]
  • [Cites] Haematologica. 2007 Jun;92(6):861-2 [17550866.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1970-5 [10760776.001]
  • [Cites] Blood. 2001 Feb 1;97(3):805-8 [11157501.001]
  • [Cites] Cancer Genet Cytogenet. 1991 May;53(1):83-90 [2036642.001]
  • (PMID = 20694842.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD56
  •  go-up   go-down


34. Löwenberg B, Beck J, Graux C, van Putten W, Schouten HC, Verdonck LF, Ferrant A, Sonneveld P, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, Breems D, de Muijnck H, Schaafsma R, Verhoef G, Döhner H, Gratwohl A, Pabst T, Ossenkoppele GJ, Maertens J, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), German Austrian AML Study Group (AMLSG), Swiss Group for Clinical Cancer Research Collaborative Group (SAKK): Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood; 2010 Apr 1;115(13):2586-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In older patients with acute myeloid leukemia (AML), the prevention of relapse has remained one of the major therapeutic challenges, with more than 75% relapses after complete remission.
  • Premature discontinuation was mainly attributable to incomplete hematologic recovery or intercurrent relapse.
  • There were no significant differences between both treatment groups with regard to relapse probabilities, nonrelapse mortality, overall survival, or disease-free survival (17% vs 16% at 5 years).
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Immunotoxins / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Age Factors. Aged. Anemia, Refractory, with Excess of Blasts / drug therapy. Anemia, Refractory, with Excess of Blasts / genetics. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Drug-Induced Liver Injury / etiology. Female. Fever / chemically induced. Gastrointestinal Diseases / chemically induced. Hematologic Diseases / chemically induced. Humans. Male. Middle Aged. Remission Induction. Sepsis / etiology. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20103782.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN77039377
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Immunotoxins; 0 / gemtuzumab
  • [Investigator] Ferrant A; Delannoy A; Maertens J; Verhoef G; Demuynck H; Bosly A; Graux C; Breems DA; Zachee P; Jaeger E; Beck J; Fischer T; von Lilienfeld-Toal M; Glasmacher A; Hartmann F; Grimminger W; Döhner H; Bargetzi M; Wernli M; Gratwohl A; Fey MF; Pabst T; Passweg J; Chalandon Y; Herr A; Wuillemin WA; Stuessi G; Schanz U; Van Der Lelie J; Biemond BJ; De Valk B; Ossenkoppele GJ; Huijgens PC; Wijermans PW; Levin MD; Schaafsma MR; Daenen SM; Vellenga E; Voogt PJ; Schouten HC; Biesma DH; Sonneveld P; Zijlmans J; Jongen-Lavrencic M; De Greef GE; Löwenberg B; Verdonck LF; Kuball J; Van Marwijk Kooy M; Milligan DW; Pocock C; Aldouri M
  •  go-up   go-down


35. Abdel Rahman H, Farrag SA, El-Attar IA: AML1/ETO Fusion Gene in de novo Pediatric Acute Myeloid Leukemia: Clinical Significance and Prognostic Implications. J Egypt Natl Canc Inst; 2007 Mar;19(1):39-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AML1/ETO Fusion Gene in de novo Pediatric Acute Myeloid Leukemia: Clinical Significance and Prognostic Implications.
  • The characterization of leukemia-associated chromosome translocations has contributed relevant insights into our understanding of leukemia pathogenesis and has provided new specific tumor markers essential in prognostic assessment and minimal residual disease studies.
  • The clinical significance and prognostic implications of this aberration, including CR rate, duration of first CR, extramedullary leukemia (EML), and survival are investigated as well.
  • Lymph nodes were enlarged in 8/15 cases (53.34%), hepatomegly was observed in 4/15 cases (26.67%), splenomegaly in 8/15 cases (53.34%), purpura in 6/15 cases (40%), while pallor was observed in all fifteen cases.Extramedullary leukemia occurred in 4/15 cases (26.67%).
  • Eight patients were in complete continuous remission (CCR), four patients (26.67%) relapsed and died during relapse, and one patient (6.67%) died in complete remission due to severe neutropenia and infection.
  • Key Words: Pediatric acute myeloid leukemia , AML1/ETO fusion gene , RT-PCR , Clinical outcome , Prognostic significance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18839034.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


36. Derwich K, Wachowiaki J, Kaczmarek-Kanoldi M, Balcerska A, Balwierz W, Chybicka A, Kowalczyk JR, Matysiak M, Jackowska T, Sońta-Jakimczyk D, Wysocki M, Chełmecka-Hanuszewicz L, Cwiklińska M, Kołtan A, Malinowska I, Odój T, Płoszyńska A, Steczowicz M, Wojciechowska V, Wójtowicz A, Polish Pediatric Leukemia/Lymphoma Study Group: [Treatment results in children with the standard risk acute lymphoblastic leukemia treated with high dose of methotrexate (5.0 g/m2). 11 years of the Polish Pediatric Leukemia/Lymphoma Study Group experience]. Przegl Lek; 2006;63(1):7-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment results in children with the standard risk acute lymphoblastic leukemia treated with high dose of methotrexate (5.0 g/m2). 11 years of the Polish Pediatric Leukemia/Lymphoma Study Group experience].
  • Relapses occured: 12 (6.2%) in bone marrow, 2 (1.0%) in central nervous system, 1 (0.5%) in testicle and in 1 (0.5%) child combined relapse was observed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Methotrexate / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


37. Pratz KW, Levis MJ: Bench to bedside targeting of FLT3 in acute leukemia. Curr Drug Targets; 2010 Jul;11(7):781-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bench to bedside targeting of FLT3 in acute leukemia.
  • FMS-Like-Tyrosine kinase-3 (FLT3) mutations are found in about 30% of cases of acute myeloid leukemia and confer an increased relapse rate and reduced overall survival.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell. 2009 Oct 23;36(2):326-39 [19854140.001]
  • [Cites] Mol Cancer Ther. 2009 Nov;8(11):3151-61 [19887542.001]
  • [Cites] Leukemia. 1995 Aug;9(8):1368-72 [7643626.001]
  • [Cites] Exp Hematol. 1995 Sep;23(10):1121-9 [7544740.001]
  • [Cites] Blood. 1996 Feb 1;87(3):1089-96 [8562934.001]
  • [Cites] Leukemia. 1996 Feb;10(2):238-48 [8637232.001]
  • [Cites] Leukemia. 1996 Apr;10(4):588-99 [8618433.001]
  • [Cites] Acta Haematol. 1996;95(3-4):218-23 [8677746.001]
  • [Cites] Eur J Immunol. 1996 Jul;26(7):1504-10 [8766553.001]
  • [Cites] J Immunol. 1996 Oct 1;157(7):2953-60 [8816402.001]
  • [Cites] Leukemia. 1996 Dec;10(12):1911-8 [8946930.001]
  • [Cites] Blood. 1998 Mar 15;91(6):1947-58 [9490677.001]
  • [Cites] Leukemia. 1998 Mar;12(3):301-10 [9529123.001]
  • [Cites] J Biol Chem. 1998 Jun 12;273(24):14962-7 [9614102.001]
  • [Cites] Leukemia. 1998 Sep;12(9):1333-7 [9737679.001]
  • [Cites] J Mol Biol. 1999 Jan 15;285(2):713-25 [9878439.001]
  • [Cites] Leukemia. 1999 Jan;13(1):38-43 [10049058.001]
  • [Cites] J Leukoc Biol. 1999 Mar;65(3):372-80 [10080542.001]
  • [Cites] Exp Hematol. 1999 Apr;27(4):663-72 [10210324.001]
  • [Cites] Blood. 1999 May 1;93(9):3074-80 [10216104.001]
  • [Cites] Br J Haematol. 1999 Apr;105(1):155-62 [10233379.001]
  • [Cites] Leukemia. 1999 Sep;13(9):1374-82 [10482988.001]
  • [Cites] Blood. 2005 Jan 1;105(1):54-60 [15345597.001]
  • [Cites] Blood. 2005 Feb 1;105(3):986-93 [15459012.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1759-67 [15498859.001]
  • [Cites] Leukemia. 2005 Jun;19(6):930-5 [15815726.001]
  • [Cites] Blood. 2005 Jul 1;106(1):265-73 [15769897.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5281-91 [16033847.001]
  • [Cites] Int J Hematol. 2005 Aug;82(2):100-7 [16146839.001]
  • [Cites] Oncogene. 2005 Oct 20;24(46):6861-9 [16007148.001]
  • [Cites] Blood. 2006 Jan 1;107(1):293-300 [16150941.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3737-46 [16585200.001]
  • [Cites] Mol Cancer Ther. 2006 Apr;5(4):995-1006 [16648571.001]
  • [Cites] Nat Chem Biol. 2006 Jul;2(7):358-64 [16783341.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1339-45 [16627759.001]
  • [Cites] Mol Cancer Ther. 2006 Jul;5(7):1774-82 [16891463.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4293-300 [16908937.001]
  • [Cites] Leuk Res. 2006 Dec;30(12):1541-6 [16603240.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3262-70 [16857985.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3477-83 [16857987.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3674-81 [16902153.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7271-8 [17189398.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1643-52 [17047150.001]
  • [Cites] Leukemia. 2007 May;21(5):877-85 [17330097.001]
  • [Cites] Oncologist. 2007 Apr;12(4):426-37 [17470685.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4575-82 [17671144.001]
  • [Cites] J Biol Chem. 2007 Oct 12;282(41):29831-46 [17698840.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):209-14 [18172272.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 6;100(3):184-98 [18230792.001]
  • [Cites] Leuk Res. 2008 Nov;32(11):1698-708 [18556063.001]
  • [Cites] J Clin Oncol. 2008 Oct 10;26(29):4714-9 [18541894.001]
  • [Cites] Blood. 2010 Feb 18;115(7):1425-32 [20007803.001]
  • [Cites] Blood. 2011 Mar 24;117(12):3294-301 [21270442.001]
  • [Cites] Leuk Res. 2009 Feb;33(2):348-50 [18573526.001]
  • [Cites] Blood. 2008 Dec 15;112(13):5161-70 [18820131.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3938-46 [19029442.001]
  • [Cites] Blood. 2009 Apr 23;113(17):4063-73 [19144992.001]
  • [Cites] Med Pediatr Oncol. 1999 Dec;33(6):525-9 [10573574.001]
  • [Cites] Oncogene. 2000 Feb 3;19(5):624-31 [10698507.001]
  • [Cites] Leukemia. 2000 Apr;14(4):675-83 [10764154.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3489-97 [10828034.001]
  • [Cites] J Exp Med. 2000 Sep 4;192(5):719-28 [10974037.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3907-14 [11090077.001]
  • [Cites] Br J Haematol. 2000 Oct;111(1):190-5 [11091200.001]
  • [Cites] Blood. 2001 Jan 1;97(1):89-94 [11133746.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2434-9 [11290608.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3589-95 [11369655.001]
  • [Cites] Br J Haematol. 2001 Jun;113(4):983-8 [11442493.001]
  • [Cites] Leukemia. 2001 Jul;15(7):1001-10 [11455967.001]
  • [Cites] Blood. 2001 Aug 1;98(3):885-7 [11468194.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1752-9 [11535508.001]
  • [Cites] Mol Cell. 2001 Sep;8(3):481-2 [11583608.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7233-9 [11585760.001]
  • [Cites] J Med Chem. 2002 Feb 28;45(5):1002-18 [11855980.001]
  • [Cites] Oncogene. 2002 Apr 11;21(16):2555-63 [11971190.001]
  • [Cites] Blood. 2002 Jun 1;99(11):3885-91 [12010785.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4326-35 [12036858.001]
  • [Cites] Blood. 2002 Jul 1;100(1):59-66 [12070009.001]
  • [Cites] Cancer Cell. 2002 Jun;1(5):421-32 [12124172.001]
  • [Cites] Cancer Cell. 2002 Jun;1(5):433-43 [12124173.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4236-43 [12154025.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1699-704 [12200684.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2941-9 [12351406.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):5148-55 [12435730.001]
  • [Cites] Bioorg Med Chem. 2003 May 1;11(9):2007-18 [12670652.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3164-73 [12468433.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3188-97 [12515727.001]
  • [Cites] Blood. 2003 May 1;101(9):3597-605 [12531805.001]
  • [Cites] Blood. 2003 Jul 15;102(2):646-51 [12663439.001]
  • [Cites] Blood. 2003 Aug 1;102(3):795-801 [12649163.001]
  • [Cites] Blood. 2003 Aug 1;102(3):881-6 [12676789.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):32892-8 [12815052.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1738-52 [12970773.001]
  • [Cites] Gene. 2003 Oct 23;317(1-2):49-57 [14604791.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5465-76 [14654525.001]
  • [Cites] Mol Cell. 2004 Jan 30;13(2):169-78 [14759363.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2266-75 [14604974.001]
  • [Cites] Oncogene. 2004 Apr 22;23(19):3338-49 [14981546.001]
  • [Cites] Blood. 2004 May 15;103(10):3669-76 [14726387.001]
  • [Cites] Blood. 2004 Aug 15;104(4):1145-50 [15126317.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6385-9 [15374944.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] Cancer Res. 1977 Jul;37(7 Pt 1):2138-46 [266416.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1210-4 [2045861.001]
  • [Cites] Blood. 1992 Nov 15;80(10):2584-93 [1384791.001]
  • [Cites] Mol Cell Biol. 1993 Oct;13(10):6572-85 [7692230.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):459-63 [7507245.001]
  • [Cites] Nature. 1994 Apr 14;368(6472):643-8 [8145851.001]
  • [Cites] Blood. 1994 May 15;83(10):2795-801 [8180375.001]
  • [Cites] N Engl J Med. 1994 Oct 6;331(14):896-903 [8078551.001]
  • [Cites] Blood. 1995 Apr 1;85(7):1762-8 [7703483.001]
  • [Cites] Cytogenet Cell Genet. 1995;70(3-4):255-7 [7789184.001]
  • [Cites] Immunity. 1995 Jul;3(1):147-61 [7621074.001]
  • [Cites] Blood. 2009 Jun 25;113(26):6567-71 [19389879.001]
  • [Cites] Blood. 2009 Oct 1;114(14):2984-92 [19654408.001]
  • (PMID = 20370649.001).
  • [ISSN] 1873-5592
  • [Journal-full-title] Current drug targets
  • [ISO-abbreviation] Curr Drug Targets
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA128864; None / None / / R01 CA128864-04; United States / NCI NIH HHS / CA / R01 CA128864-04
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Drugs, Investigational; 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Number-of-references] 126
  • [Other-IDs] NLM/ NIHMS263725; NLM/ PMC3023996
  •  go-up   go-down


38. Pui CH, Howard SC: Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol; 2008 Mar;9(3):257-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With 5-year event-free survival of 80% now commonplace for paediatric acute lymphoblastic leukaemia (ALL), and 50% for paediatric acute myeloid leukaemia (AML), recent efforts have focused on optimum risk-directed treatment.
  • Because cranial irradiation can cause many acute and late complications (eg, second cancers, neurocognitive deficits, endocrine disorders, and growth impairment), it has been largely replaced by intensive intrathecal treatment and systemic chemotherapy.
  • Prophylactic cranial irradiation (12-18 Gy) is given to 2-20% of patients with ALL who have an increased risk of CNS relapse (such as T-cell immunophenotype, overt CNS disease, high-risk cytogenetic features, or poor response to remission induction treatment), and for the estimated 2% of patients with AML who have overt CNS disease at diagnosis.
  • Although this strategy restricts CNS relapse to 3-8% of patients, several challenges remain.
  • Methods need to eliminate relapse without the use of cranial irradiation in very high-risk patients.
  • Perhaps the most formidable challenge is to treat children with CNS relapse after a short initial remission or cranial irradiation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System. Cranial Irradiation / adverse effects. Leukemia, Myeloid, Acute. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18308251.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Grant] United States / PHS HHS / / BETA7824; United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / CA-36401; United States / NCI NIH HHS / CA / CA-51001; United States / NCI NIH HHS / CA / CA-60419; United States / NIGMS NIH HHS / GM / GM-61393
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 83
  •  go-up   go-down


39. Avramis VI, Spence SA: Clinical pharmacology of asparaginases in the United States: asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric ALL patients. J Pediatr Hematol Oncol; 2007 Apr;29(4):239-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the past 25 years, effective new drugs along with better treatment decisions based on disease factors have resulted in significantly improved clinical outcomes in acute lymphoblastic leukemia.
  • Despite these successes in the last 2 decades, 15% to 25% of acute lymphoblastic leukemia patients relapse.
  • [MeSH-major] Antineoplastic Agents / pharmacokinetics. Asparaginase / pharmacokinetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414566.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


40. Lee S, Kim YJ, Chung NG, Lim J, Lee DG, Kim HJ, Min CK, Lee JW, Min WS, Kim CC: The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer; 2009 Feb 1;115(3):561-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
  • BACKGROUND: Previously, the authors demonstrated the positive impact of imatinib on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL).
  • With a median follow-up of 49 months after stem cell transplantation, the 4-year relapse rate and disease-free survival rate were 21.2% and 69.8%, respectively.
  • A reduction in BCR-ABL transcript levels of at least 3 log after the first 4-week imatinib therapy was identified as the most powerful predictor of lower relapse (12.1% vs 45.1%, P = .011) and better disease-free survival (82.1% vs 41.7%, P = .009) rates.
  • CONCLUSIONS: Prospective assessment of the extent of minimal residual disease reduction after the first 4-week imatinib therapy may allow the authors to identify subgroups of Ph-positive ALL transplants at high risk of relapse.
  • [MeSH-major] Neoplasm, Residual / diagnosis. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Pyrimidines / therapeutic use. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19117346.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


41. Petersen WC, Schlis KD, Braverman RS, Carlson I, Liang X, Wang M: Pseudohypopyon: Extramedullary relapse of acute myelogenous leukemia with poor prognosis. Pediatr Blood Cancer; 2009 Jul;52(7):885-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudohypopyon: Extramedullary relapse of acute myelogenous leukemia with poor prognosis.
  • She was diagnosed with acute myelogenous leukemia.
  • Towards the end of her second course of induction she developed pseudohypopyon in each eye on consecutive days, heralding a central nervous system relapse.
  • [MeSH-major] Anterior Chamber / pathology. Eye Diseases / diagnosis. Leukemia, Myelomonocytic, Acute / diagnosis. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Cytarabine / therapeutic use. Female. Humans. Infant. Injections, Spinal. Prognosis. Suppuration / diagnosis

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Eye Diseases.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 19090546.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
  •  go-up   go-down


42. Gallay N, Dos Santos C, Cuzin L, Bousquet M, Simmonet Gouy V, Chaussade C, Attal M, Payrastre B, Demur C, Récher C: The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. Leukemia; 2009 Jun;23(6):1029-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia.
  • The phosphoinositide 3-kinase/Akt pathway is an important signalling pathway governing cell survival and proliferation in acute myeloid leukaemia (AML).
  • Thr308(high) patients had significantly shorter overall survival (11 vs 47 months; P=0.01), event-free survival (9 vs 26 months; P=0.005) and relapse-free survival (10 months vs not reached; P=0.02) than Thr308(low) patients.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Proto-Oncogene Proteins c-akt / metabolism


43. Roy A, Bradburn M, Moorman AV, Burrett J, Love S, Kinsey SE, Mitchell C, Vora A, Eden T, Lilleyman JS, Hann I, Saha V, Medical Research Council Childhood Leukaemia Working Party: Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial. Br J Haematol; 2005 Apr;129(1):35-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial.
  • We report on the outcome of children with Philadelphia positive acute lymphoblastic leukaemia (Ph+ ALL) treated on the UK Medical Research Council (MRC) trial for childhood ALL, MRC ALL 97, between January 1997 and June 2002.
  • BMT in CR1 appeared to reduce the risk of a subsequent BM relapse.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15801953.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 14840
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 7S5I7G3JQL / Dexamethasone; 9PHQ9Y1OLM / Prednisolone; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


44. Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R, Matteucci P, Bregni M, Scimè R, Narni F, Pogliani E, Locasciulli A, Milani R, Carniti C, Bacigalupo A, Rambaldi A, Bonifazi F, Olivieri A, Gianni AM, Tarella C, Gruppo Italiano Trapianto di Midollo Osseo: Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia; 2007 Nov;21(11):2316-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary study end point was non-relapse mortality (NRM).
  • The results show that frequencies were as follows: cumulative NRM at 3 years, 14%; acute and chronic graft-versus-host disease (GVHD) 35 and 52%, respectively; 3-year overall survival (OS), 69% for LG-NHL, 69% for HG-NHL, 45% for MCL and 32% for HD (P=0.058); and 3-year relapse incidence, 29, 31, 35 and 81%, respectively (P<0.001).
  • Relapse risk differed significantly at 3 years between follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) (14 versus 46%, P=0.04).
  • On multivariate analysis, OS was influenced by chemorefractory disease (hazard ratio (HR)=3.6), diagnosis of HD (HR=3.5), and acute GVHD (HR=5.9).

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17597807.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


45. Gronda M, Brandwein J, Minden MD, Pond GR, Schuh AC, Wells RA, Messner H, Chun K, Schimmer AD: Assessment of the downstream portion of the mitochondrial pathway of caspase activation in patients with acute myeloid leukemia. Apoptosis; 2005 Dec;10(6):1285-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of the downstream portion of the mitochondrial pathway of caspase activation in patients with acute myeloid leukemia.
  • Most chemotherapeutic agents used in the treatment of acute myeloid leukemia (AML) induce apoptosis by triggering the mitochondrial pathway of caspase activation.
  • Thus, functional defects in the distal portion of the mitochondrial pathway of caspase activation may help explain the nature of response and relapse after treatment.
  • [MeSH-major] Caspases / metabolism. Leukemia, Myeloid, Acute / enzymology. Mitochondria / enzymology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16215669.001).
  • [ISSN] 1360-8185
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Caspase Inhibitors; 0 / Enzyme Inhibitors; 0 / Inhibitor of Apoptosis Proteins; 8L70Q75FXE / Adenosine Triphosphate; 9007-43-6 / Cytochromes c; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


46. Castro-Malaspina H, Jabubowski AA, Papadopoulos EB, Boulad F, Young JW, Kernan NA, Perales MA, Small TN, Hsu K, Chiu M, Heller G, Collins NH, Jhanwar SC, van den Brink M, Nimer SD, O'Reilly RJ: Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. Biol Blood Marrow Transplant; 2008 Apr;14(4):458-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • From 1985 to 2004, 49 patients with advanced myelodysplastic syndromes (MDS) (> or =5% blasts) or acute myeloid leukemia (AML) transformed from MDS underwent T cell depleted bone marrow or peripheral blood hematopoietic stem cell transplantation (HSCT) from HLA-identical siblings following conditioning with a myeloablative regimen that included total body irradiation (44 patients) or busulfan (5 patients).
  • Prior to transplantation, 22 of the 36 treated patients were in hematologic remission; 4 were in a second refractory cytopenia phase (26 responders); 8 had failed to achieve remission; and 2 of the responders had progression or relapse of their MDS (10 failures).
  • Only 3 patients developed acute GVHD (aGVHD) (grades I and III) and 1 chronic GVHD (cGVHD).
  • The cumulative incidence (CI) of relapse at 2-yrs post-transplantation for the responders was 23%; for the untreated group was 38%; and for the failures was 50%.
  • The CI of non-relapse mortality at 2-yrs post-transplantation, for the responders was 23%; for the untreated group was 38%; and for the failures was 40%.

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342789.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA023766; United States / NCI NIH HHS / CA / P30 CA008748; United States / NHLBI NIH HHS / HL / R01 HL088134
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens
  • [Other-IDs] NLM/ NIHMS43830; NLM/ PMC4498391
  •  go-up   go-down


47. Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP, Halter J, Keating A, Marks DI, McCarthy PL, Olavarria E, Stadtmauer EA, Abecasis M, Gupta V, Khoury HJ, George B, Hale GA, Liesveld JL, Rizzieri DA, Antin JH, Bolwell BJ, Carabasi MH, Copelan E, Ilhan O, Litzow MR, Schouten HC, Zander AR, Horowitz MM, Maziarz RT: Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood; 2008 Oct 15;112(8):3500-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.
  • Imatinib mesylate (IM, Gleevec) has largely supplanted allogeneic hematopoietic cell transplantation (HCT) as first line therapy for chronic myeloid leukemia (CML).
  • Among patients in first chronic phase, IM therapy before HCT was associated with better survival but no statistically significant differences in treatment-related mortality, relapse, and leukemia-free survival.
  • Better HLA-matched donors, use of bone marrow, and transplantation within one year of diagnosis were also associated with better survival.
  • Among patients transplanted with advanced CML, use of IM before HCT was not associated with treatment-related mortality, relapse, leukemia-free survival, or survival.
  • Acute graft-versus-host disease rates were similar between IM(+) and IM(-) groups regardless of leukemia phase.


48. Elorza I, Palacio C, Dapena JL, Gallur L, Sánchez de Toledo J, Díaz de Heredia C: Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia. Haematologica; 2010 Jun;95(6):936-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia.
  • BACKGROUND: The presence of minimal residual disease detected by polymerase chain reaction techniques prior to allogeneic hematopoietic stem cell transplantation has proven to be an independent prognostic factor for poor outcome in children with acute lymphoblastic leukemia.
  • DESIGN AND METHODS: The aim of this study was to ascertain whether the presence of minimal residual disease detected by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation is related to outcome in children acute lymphoblastic leukemia.
  • Minimal residual disease was quantified by multiparametric flow cytometry at a median of 10 days prior to hematopoietic stem cell transplantation in 31 children (age range, 10 months to 16 years) with acute lymphoblastic leukemia.
  • Bivariate analysis identified pre-transplant minimal residual disease as the only significant factor for relapse and also for death (P<0.01).
  • CONCLUSIONS: The presence of minimal residual disease measured by multiparametric flow cytometry identified a group of patients with a 9.5-fold higher risk of relapse and a 3.2-fold higher risk of death than those without minimal residual disease.
  • [MeSH-major] Flow Cytometry / methods. Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1998 Dec 1;92(11):4072-9 [9834212.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):550-4 [9492773.001]
  • [Cites] Med Oncol. 1999 Sep;16(3):177-87 [10523797.001]
  • [Cites] Br J Haematol. 2005 Mar;128(6):774-82 [15755280.001]
  • [Cites] Bone Marrow Transplant. 2005 Mar;35 Suppl 1:S49-52 [15812531.001]
  • [Cites] Bone Marrow Transplant. 2005 Jul;36(2):163-9 [15937507.001]
  • [Cites] Haematologica. 2005 Nov;90(11):1516-23 [16266899.001]
  • [Cites] Pediatr Blood Cancer. 2007 Jan;48(1):93-100 [16521130.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):16-24 [17194902.001]
  • [Cites] Leukemia. 2007 Apr;21(4):622-6 [17301806.001]
  • [Cites] Clin Transl Oncol. 2008 Feb;10(2):117-24 [18258511.001]
  • [Cites] Cytometry B Clin Cytom. 2008 Nov;74(6):331-40 [18548617.001]
  • [Cites] Br J Haematol. 2008 Nov;143(4):481-9 [18710378.001]
  • [Cites] Br J Haematol. 2009 Jan;144(1):107-15 [19016726.001]
  • [Cites] J Clin Oncol. 2009 Jan 20;27(3):377-84 [19064980.001]
  • [Cites] Leukemia. 1999 Dec;13(12):2079-86 [10602432.001]
  • [Cites] Bone Marrow Transplant. 2000 Feb;25(4):395-9 [10723582.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2691-6 [11023499.001]
  • [Cites] Haematologica. 2001 Jun;86(6):586-95 [11418367.001]
  • [Cites] Leukemia. 2001 Sep;15(9):1485-7 [11516112.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1982-4 [11535539.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1668-72 [12200679.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1013-34 [12764363.001]
  • [Cites] Br J Haematol. 2003 Sep;122(5):788-94 [12930390.001]
  • [Cites] Bone Marrow Transplant. 2003 Oct;32(8):849-51 [14520434.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1696-705 [15117992.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1630-6 [15295608.001]
  • [Cites] Blood. 1990 Jul 1;76(1):163-71 [1973061.001]
  • [Cites] Cytometry. 1999 Aug 15;38(4):139-52 [10440852.001]
  • (PMID = 20179088.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2878791
  •  go-up   go-down


49. Eser B, Altuntas F, Soyuer I, Er O, Canoz O, Coskun HS, Cetin M, Unal A: Acute lymphoblastic leukemia associated with brucellosis in two patients with fever and pancytopenia. Yonsei Med J; 2006 Oct 31;47(5):741-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia associated with brucellosis in two patients with fever and pancytopenia.
  • Herein, two cases with fever and pancytopenia, diagnosed as simultaneous acute lymphoblastic leukemia and brucellosis are presented.
  • The first patient is in complete remission; the other recovered from the brucellosis, but later died due to a leukemic relapse.
  • [MeSH-major] Brucellosis / complications. Pancytopenia / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Brucellosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Pediatr Oncol. 2000 Nov;35(5):496-7 [11070484.001]
  • [Cites] Braz J Med Biol Res. 1998 Jan;31(1):77-84 [9686182.001]
  • [Cites] Vopr Onkol. 1979;25(6):76-80 [111416.001]
  • [Cites] J Infect Dis. 1983 Mar;147(3):445-9 [6833793.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1988;82(2):336 [3188167.001]
  • [Cites] Am J Med. 1989 Jan;86(1):111-4 [2910082.001]
  • [Cites] Enferm Infecc Microbiol Clin. 1990 Jan;8(1):19-24 [2095900.001]
  • [Cites] Infection. 1993 Jan-Feb;21(1):23-6 [8449576.001]
  • [Cites] Acta Haematol. 1993;89(3):132-6 [8362601.001]
  • [Cites] Sangre (Barc). 1995 Apr;40(2):165-6 [7784948.001]
  • [Cites] Eur J Pediatr. 1996 Jan;155(1):1-6 [8750800.001]
  • [Cites] Vet Immunol Immunopathol. 1996 Nov;54(1-4):309-19 [8988876.001]
  • [Cites] Acta Med Okayama. 1998 Feb;52(1):63-5 [9548996.001]
  • [Cites] Am J Gastroenterol. 1998 May;93(5):854-5 [9625158.001]
  • [Cites] Wiad Lek. 1968 Oct 15;21(20):1819-21 [5702478.001]
  • (PMID = 17066520.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2687762
  •  go-up   go-down


50. Amjad AI, Söder O, Sultana T: Role of testicular interleukin-1alpha tIL-1alpha in testicular physiology and disease. J Coll Physicians Surg Pak; 2006 Jan;16(1):55-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, the mature 17 kDa tIL-1alpha has also been implicated in pathologies such as orchitis, relapse of acute lymphoblastic leukemia (ALL) in the testis and infertility disorders in men.

  • MedlinePlus Health Information. consumer health - Testicular Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16441992.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Interleukin-1
  • [Number-of-references] 66
  •  go-up   go-down


51. Jones LK, Saha V: Philadelphia positive acute lymphoblastic leukaemia of childhood. Br J Haematol; 2005 Aug;130(4):489-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Philadelphia positive acute lymphoblastic leukaemia of childhood.
  • On current chemotherapeutic regimens, children with Philadelphia positive acute lymphoblastic leukaemia show a heterogeneous response to treatment.
  • Relapse on treatment is common and remission is sustained in a proportion of cases only after allogeneic stem cell transplantation (allo-SCT).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16098062.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 14840
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Number-of-references] 123
  •  go-up   go-down


52. Hsu KC, Pinto-Agnello C, Gooley T, Malkki M, Dupont B, Petersdorf EW: Hematopoietic stem cell transplantation: killer immunoglobulin-like receptor component. Tissue Antigens; 2007 Apr;69 Suppl 1:42-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recognition of recipient human leukocyte antigen (HLA) class I ligand by donor natural killer cell killer immunoglobulin-like receptors (KIR) has been proposed as the basis for donor allograft reactivity against malignancy leading to reduction in posttransplant relapse and higher survival for acute myelogenous leukemia.
  • Analysis of KIR ligand effects in 1770 patients undergoing myeloablative T-replete hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors showed that lack of KIR ligand in patients for inhibitory KIR was associated with lower hazards of relapse in leukemia patients with in HLA-mismatched transplants [hazard ratio (HR): 0.061; 95% confidence interval (CI): 0.43-0.85; P-value = 0.004].
  • Absence of HLA-C group 2 or HLA-Bw4 KIR ligands were each associated with lower hazards of relapse (HR: 0.47; 95% CI: 0.28-0.79; P-value = 0.004; HR: 0.56; 95% CI: 0.33-0.97; P-value = 0.04, respectively).
  • Based on these analyses, recipient homozygosity for HLA-B or -C epitopes that define KIR ligands is likely to be a predictive factor for leukemia relapse following myeloablative HCT from unrelated donors.

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17445161.001).
  • [ISSN] 0001-2815
  • [Journal-full-title] Tissue antigens
  • [ISO-abbreviation] Tissue Antigens
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI 49213; United States / NIAID NIH HHS / AI / AI069197; United States / NIAID NIH HHS / AI / AI33484
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / HLA-B Antigens; 0 / HLA-C Antigens; 0 / Ligands; 0 / Receptors, Immunologic; 0 / Receptors, KIR
  •  go-up   go-down


53. Ozdogu H, Boga C, Kizilkilic E, Kozanoglu I, Karakus S, Sahin FI, Unalan D, Haberal M: The first 2 years of clinical experience with peripheral blood stem cell transplantation for various hematological malignancies: results from a single Baskent University Center. Transplant Proc; 2007 May;39(4):1257-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four patients with acute myeloblastic leukemia underwent nonmyeloablative allogeneic peripheral stem cell transplantation.
  • One refractory patient with >90% engraftment had late autologous reconstitution at 3 months with evidence of relapse.

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17524948.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; BZ114NVM5P / Mitoxantrone; Q41OR9510P / Melphalan
  •  go-up   go-down


54. Shah A, Stiller CA, Kenward MG, Vincent T, Eden TO, Coleman MP: Childhood leukaemia: long-term excess mortality and the proportion 'cured'. Br J Cancer; 2008 Jul 8;99(1):219-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Average time to cure is defined as the time since diagnosis at which the excess mortality rate has declined to or below a predetermined small value.
  • Average time to cure increased from 12 years (95% confidence interval (CI): 11-14) to 19 years (95% CI: 14-26) for lymphoid leukaemia (average annual increase of 0.3 years; P<0.001), but remained at about 5 years for acute nonlymphoblastic leukaemia.
  • The proportion of children cured of leukaemia has risen dramatically, but the period of excess mortality associated with lymphoid leukaemia has also increased, possibly because of late relapse, secondary malignancy and toxicity from treatment.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1998 Oct 1;92(7):2334-7 [9746771.001]
  • [Cites] J Natl Cancer Inst. 1996 Mar 6;88(5):270-8 [8614005.001]
  • [Cites] Br J Cancer. 2004 Nov 29;91(11):1905-10 [15534607.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):67-75 [15982346.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7936-41 [16258093.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2130-8 [16304572.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] Br J Cancer. 2007 Apr 10;96(7):1147-52 [17342086.001]
  • [Cites] Br J Haematol. 2000 Mar;108(3):531-43 [10759711.001]
  • [Cites] Blood. 2000 May 1;95(9):2770-5 [10779419.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2307-20 [11187922.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3163-72 [11432882.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3173-81 [11432883.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4257-64 [12036851.001]
  • [Cites] Br J Haematol. 2003 Aug;122(3):345-59 [12877662.001]
  • [Cites] N Engl J Med. 2003 Aug 14;349(7):640-9 [12917300.001]
  • [Cites] Br J Haematol. 2004 Jan;124(1):33-46 [14675406.001]
  • [Cites] Pediatr Blood Cancer. 2004 Jun;42(7):563-73 [15127410.001]
  • [Cites] Lancet. 1986 Feb 22;1(8478):408-11 [2868339.001]
  • [Cites] Arch Dis Child. 1989 Jun;64(6):798-807 [2774614.001]
  • [Cites] J Clin Epidemiol. 1997 Feb;50(2):211-6 [9120515.001]
  • [Cites] Int J Cancer. 1998 Jul 29;77(3):322-9 [9663589.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2848-53 [9704738.001]
  • [Cites] N Engl J Med. 1991 Nov 7;325(19):1330-6 [1922234.001]
  • [Cites] BMJ. 1994 Jul 16;309(6948):162-6 [8044095.001]
  • [Cites] IARC Sci Publ. 1994;(128):1-302 [7698823.001]
  • [Cites] Stat Med. 1999 Feb 28;18(4):441-54 [10070685.001]
  • (PMID = 18594545.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2453011
  •  go-up   go-down


55. Liu HC, Hung GY, Yen HJ, Hsieh MY, Chiou TJ: Acute sciatica: an unusual presentation of extramedullary relapse of acute lymphoblastic leukemia. Int J Hematol; 2007 Aug;86(2):163-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute sciatica: an unusual presentation of extramedullary relapse of acute lymphoblastic leukemia.
  • A 10-year-old boy who had been treated for acute lymphoblastic leukemia presented with persistent numbness of the left big toe and progressive pain of the ipsilateral lower leg.
  • He had received allogeneic bone marrow transplantation 3 months after a testicular relapse.
  • He was in hematologic remission at admission but as progressive swelling of his left leg continued, bone marrow relapse developed.
  • This case represents a rare neurologic complication of what is currently an uncommon presentation for relapse of acute lymphoblastic leukemia, with acute sciatica and without coexisting epidural or leptomeningeal leukemia.
  • [MeSH-major] Leukemic Infiltration / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Sciatica / etiology
  • [MeSH-minor] Acute Disease. Child. Humans. Leg / pathology. Magnetic Resonance Imaging. Male. Muscle, Skeletal / injuries. Muscle, Skeletal / pathology. Recurrence. Sciatic Nerve / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Sciatica.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Formos Med Assoc. 1998 Apr;97(4):252-60 [9585676.001]
  • [Cites] Arch Neurol. 1994 Jun;51(6):618-22 [8198473.001]
  • [Cites] J Trauma. 1999 Nov;47(5):986-91 [10568739.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Aug;19(2):439-44 [2394621.001]
  • [Cites] Haematologica. 2006 May;91(5 Suppl):ECR07 [16709515.001]
  • [Cites] Bone Marrow Transplant. 2000 Jul;26(2):147-52 [10918424.001]
  • [Cites] Neurology. 1987 Mar;37(3):474-7 [3469539.001]
  • [Cites] Ann Hematol. 2003 Feb;82(2):124-6 [12601494.001]
  • [Cites] Cancer. 1988 Nov 1;62(9):2047-50 [3167817.001]
  • [Cites] Laryngoscope. 2002 Feb;112(2):235-7 [11889376.001]
  • [Cites] Br J Haematol. 1998 Jul;102(2):423-38 [9695956.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 1990 Aug;19(3):259-64 [2210952.001]
  • [Cites] Ann Intern Med. 1991 Jul 1;115(1):13-8 [2048858.001]
  • (PMID = 17875532.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


56. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, Linda S, Martin PL, Pullen DJ, Viswanatha D, Willman CL, Winick N, Camitta BM, Children's Oncology Group: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood; 2008 Jun 15;111(12):5477-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
  • Minimal residual disease (MRD) is an important predictor of relapse in acute lymphoblastic leukemia (ALL), but its relationship to other prognostic variables has not been fully assessed.
  • [MeSH-major] Biomarkers, Tumor. Neoplasm, Residual / mortality. Neoplasm, Residual / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Jul 1;100(1):52-8 [12070008.001]
  • [Cites] Leukemia. 2002 Aug;16(8):1432-6 [12145681.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2399-402 [12239148.001]
  • [Cites] N Engl J Med. 1998 Jun 4;338(23):1663-71 [9614257.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):591-8 [9718378.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1731-8 [9848348.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3774-81 [9850021.001]
  • [Cites] Leukemia. 1999 Jan;13(1):110-8 [10049045.001]
  • [Cites] Leukemia. 1999 Apr;13(4):558-67 [10214862.001]
  • [Cites] Br J Haematol. 2005 Mar;128(6):774-82 [15755280.001]
  • [Cites] Haematologica. 2005 Nov;90(11):1516-23 [16266899.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Blood. 2006 Jul 15;108(2):711-7 [16822902.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1109-12 [16885052.001]
  • [Cites] Blood. 2007 Feb 1;109(3):926-35 [17003380.001]
  • [Cites] Br J Haematol. 2003 Jan;120(1):74-9 [12492579.001]
  • [Cites] Leukemia. 2003 Jan;17(1):138-48 [12529671.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):704-9 [12586809.001]
  • [Cites] Blood. 2000 Feb 1;95(3):790-4 [10648387.001]
  • [Cites] Leukemia. 2000 May;14(5):816-25 [10803512.001]
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):295-308 [10830736.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1619-20 [10979670.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2691-6 [11023499.001]
  • [Cites] Leukemia. 2000 Nov;14(11):1939-43 [11069029.001]
  • [Cites] Br J Haematol. 2000 Dec;111(4):1080-6 [11167743.001]
  • [Cites] Leukemia. 2001 Feb;15(2):283-5 [11236947.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2115-20 [11264179.001]
  • [Cites] Leukemia. 2001 May;15(5):716-27 [11368431.001]
  • [Cites] Leukemia. 2001 Aug;15(8):1185-92 [11480560.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1253-8 [11830473.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1094-104 [11844835.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1952-8 [11877265.001]
  • [Cites] Curr Opin Hematol. 2003 Jul;10(4):290-6 [12799535.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1566-72 [12886244.001]
  • [Cites] Curr Oncol Rep. 2003 Sep;5(5):413-8 [12895394.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1700-6 [12970767.001]
  • [Cites] Leuk Lymphoma. 2003 Sep;44(9):1445-55 [14565643.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2318-57 [14562125.001]
  • [Cites] Rev Clin Exp Hematol. 2003 Sep;7(3):292-323 [15024971.001]
  • [Cites] Leukemia. 2004 Apr;18(4):709-19 [14961040.001]
  • [Cites] Leukemia. 2004 May;18(5):934-8 [15029212.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1630-6 [15295608.001]
  • [Cites] Haematologica. 2004 Oct;89(10):1271-3 [15477219.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Blood. 1990 Oct 15;76(8):1449-63 [2207320.001]
  • [Cites] Br J Haematol. 1991 Oct;79(2):211-7 [1958478.001]
  • [Cites] Blood. 1992 Jun 15;79(12):3316-24 [1596572.001]
  • [Cites] Leuk Lymphoma. 1994;13 Suppl 1:87-90 [8075587.001]
  • [Cites] Br J Haematol. 1995 Nov;91(3):640-6 [8555067.001]
  • [Cites] Leukemia. 1995 Dec;9(12):1985-9 [8609706.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):389-98 [8636748.001]
  • [Cites] Eur J Histochem. 1996;40 Suppl 1:39-42 [8839698.001]
  • [Cites] Neoplasma. 1996;43(6):367-72 [8996560.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1150-7 [9060558.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2222-30 [9196134.001]
  • [Cites] Br J Haematol. 1997 Jul;98(1):140-6 [9233577.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1717-26 [9351539.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):550-4 [9492773.001]
  • [Cites] Br J Haematol. 1998 Apr;101(1):158-64 [9576196.001]
  • [Cites] Blood. 2007 Feb 1;109(3):910-5 [17023577.001]
  • [Cites] Leukemia. 2007 Apr;21(4):604-11 [17287850.001]
  • [Cites] Leukemia. 2007 Apr;21(4):706-13 [17287857.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1607-11 [17485550.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2315-23 [11895762.001]
  • [Cites] Leukemia. 2002 May;16(5):928-36 [11986956.001]
  • [Cites] Best Pract Res Clin Haematol. 2002 Mar;15(1):37-57 [11987915.001]
  • [Cites] Best Pract Res Clin Haematol. 2002 Mar;15(1):71-90 [11987917.001]
  • (PMID = 18388178.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00005585/ NCT00005596/ NCT00005603
  • [Grant] United States / NCI NIH HHS / CA / R01 CA086011; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / R01 CA86011; United States / NCI NIH HHS / CA / U10 CA98543
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  • [Other-IDs] NLM/ PMC2424148
  •  go-up   go-down


57. Huang Z, Chai YH, Cen JN, He HL, Li J: [Expression of CYP3A5 mRNA in children with acute leukemia]. Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jul;11(7):549-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of CYP3A5 mRNA in children with acute leukemia].
  • So far the studies on CYP3A5 gene has only been focused on the leukemia cell lines.
  • This study examined the polymorphism of CYP3A5 and tried to find the possible relationship between CYP3A5 gene expression and treatment outcome or prognosis in children with acute leukemia.
  • METHODS: The genotype distribution of CYP3A5-6986A/G gene polymorphism was detected with the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method in 66 children with newly diagnosed acute leukemia (AL) and 22 control individuals.
  • In patients with acute lymphocytic leukaemia (ALL), the complete remission (CR) rate in the group with a low expression of wt-CYP3A5 mRNA was significantly higher than that in the group with a high expression (p<0.05).
  • The expression increased before ALL relapse compared with that in CR in a patient, while in the other patient, the expression was kept in a low level and the patient remained in CR CONCLUSIONS: wt-CYP3A5 mRNA expression was associated with the treatment outcome and prognosis in children with AL.
  • Dynamic monitoring for wt-CYP3A5 mRNA expression in the bone marrow may be useful in the evaluation of the disease severity in childhood acute leukemia.
  • [MeSH-major] Cytochrome P-450 CYP3A / genetics. Leukemia / enzymology. RNA, Messenger / analysis
  • [MeSH-minor] Acute Disease. Child. Genotype. Humans. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19650988.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 1.14.14.1 / CYP3A5 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP3A
  •  go-up   go-down


58. Wu S, Gessner R, Taube T, Korte A, von Stackelberg A, Kirchner R, Henze G, Seeger K: Chemokine IL-8 and chemokine receptor CXCR3 and CXCR4 gene expression in childhood acute lymphoblastic leukemia at first relapse. J Pediatr Hematol Oncol; 2006 Apr;28(4):216-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemokine IL-8 and chemokine receptor CXCR3 and CXCR4 gene expression in childhood acute lymphoblastic leukemia at first relapse.
  • In this study, we examined the gene expression of interleukin (IL)-8, CXCR3, and CXCR4 in leukemic cells from 100 children with relapsed B-cell progenitors (BCP) acute lymphoblastic leukemia (ALL), using quantitative real-time polymerase chain reaction (RT-PCR).
  • The CXCR4 expression significantly correlated with known prognostic factors at relapse: time point and site of relapse.
  • Patients who had a combined BM relapse (n=21) had lower IL-8 and CXCR4 expression than those who had an isolated BM relapse (n=79).
  • [MeSH-major] Bone Marrow / pathology. Gene Expression Regulation, Neoplastic. Interleukin-8 / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, CXCR4 / genetics. Receptors, Chemokine / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16679918.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCR3 protein, human; 0 / DNA Primers; 0 / Interleukin-8; 0 / RNA, Neoplasm; 0 / Receptors, CXCR3; 0 / Receptors, CXCR4; 0 / Receptors, Chemokine
  •  go-up   go-down


59. Elmaagacli AH: Molecular methods used for detection of minimal residual disease following hematopoietic stem cell transplantation in myeloid disorders. Methods Mol Med; 2007;134:161-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Monitoring of minimal residual disease (MRD) in patients with acute or chronic myeloid disorders is routinely performed after allogeneic or autologous transplantation.
  • The detection of MRD helps to identify patients who are at high risk for leukemic relapse after transplantation.
  • Here, we describe the most used sensitive real-time reverse-transcription (RT)-PCR methods for chronic and acute myeloid disorders.
  • Besides protocols for real-time RT-PCR and multiplex RT-PCR procedures for the most common fusion-gene transcripts in acute and chronic myeloid disorders, methods for detection of disease-specific genetic mutated alterations as FLT3 gene-length mutations, and aberrantly expressed genes as WT1 gene transcripts, are described in detail for daily use.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid / therapy. Molecular Diagnostic Techniques / methods. Neoplasm, Residual / diagnosis

  • Genetic Alliance. consumer health - Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17666750.001).
  • [ISSN] 1543-1894
  • [Journal-full-title] Methods in molecular medicine
  • [ISO-abbreviation] Methods Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / CBFbeta-MYH11 fusion protein; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


60. Labar B, Suciu S, Willemze R, Muus P, Marie JP, Fillet G, Berneman Z, Jaksic B, Feremans W, Bron D, Sinnige H, Mistrik M, Vreugdenhil G, De Bock R, Nemet D, Gilotay C, Amadori S, de Witte T, EORTC Leukemia Group: Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group. Haematologica; 2010 Sep;95(9):1489-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group.
  • BACKGROUND: Corticosteroids are a standard component of the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma.
  • DESIGN AND METHODS: Adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma were randomized to receive, as part of their induction therapy on days 1-8 and 15-22, either dexamethasone 8 mg/m(2) or prednisolone 60 mg/m(2).
  • The 6-year cumulative incidences of relapse were 49.8% and 53.5% (Gray's test: P=0.30) while the 6-year cumulative incidences of death were 18% and 9% (Gray's test: P=0.07).
  • CONCLUSIONS: In the ALL-4 trial in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma, treatment with dexamethasone did not show any advantage over treatment with prednisolone.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • ORBi (University of Liege). Free full Text at ORBi .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1986 Mar 20;314(12):729-35 [3513012.001]
  • [Cites] J Clin Endocrinol Metab. 1975 Jun;40(6):1073-7 [1133157.001]
  • [Cites] Med Pediatr Oncol. 1991;19(4):269-75 [2056971.001]
  • [Cites] Bone Marrow Transplant. 1994 Nov;14(5):767-74 [7889010.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):1-12 [7743230.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):911-8 [8622039.001]
  • [Cites] Med Pediatr Oncol. 1996 Aug;27(2):114-21 [8649318.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2370-6 [8708730.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2788-801 [15481055.001]
  • [Cites] Br J Haematol. 2005 Jun;129(6):734-45 [15952999.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Leukemia. 2007 Apr;21(4):593-4 [17301807.001]
  • [Cites] Semin Hematol. 2007 Oct;44(4):267-73 [17961726.001]
  • [Cites] Health Qual Life Outcomes. 2008;6:103 [19036151.001]
  • [Cites] Pediatr Blood Cancer. 2009 Dec;53(6):984-91 [19621425.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):18-24 [8558195.001]
  • [Cites] Leukemia. 2000 Mar;14(3):356-63 [10720126.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1964-9 [10760775.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1307-25, ix [11147225.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2193-4 [11187910.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1211-8 [11222362.001]
  • [Cites] Pediatr Hematol Oncol. 2001 Apr-May;18(3):187-91 [11293286.001]
  • [Cites] Rev Clin Exp Hematol. 2002 Jun;6(2):114-41; discussion 200-2 [12196212.001]
  • [Cites] Blood. 2003 May 15;101(10):3809-17 [12531809.001]
  • [Cites] Cancer. 2003 Jun 1;97(11):2898-903 [12767105.001]
  • [Cites] Haematologica. 2004 Jul;89(7):809-17 [15257932.001]
  • [Cites] J Clin Oncol. 1987 Feb;5(2):202-7 [3806166.001]
  • (PMID = 20378563.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA011488; United States / NCI NIH HHS / CA / CA11488-25; United States / NCI NIH HHS / CA / CA11489-39
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 7S5I7G3JQL / Dexamethasone; 9PHQ9Y1OLM / Prednisolone
  • [Other-IDs] NLM/ PMC2930949
  •  go-up   go-down


61. Alessandrino EP, Della Porta MG, Bacigalupo A, Van Lint MT, Falda M, Onida F, Bernardi M, Iori AP, Rambaldi A, Cerretti R, Marenco P, Pioltelli P, Malcovati L, Pascutto C, Oneto R, Fanin R, Bosi A, Gruppo Italiano Trapianto di Midollo Osseo (GITMO): WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood; 2008 Aug 1;112(3):895-902
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five-year overall survival (OS) was 80% in refractory anemias, 57% in refractory cytopenias, 51% in refractory anemia with excess blasts 1 (RAEB-1), 28% in RAEB-2, and 25% in acute leukemia from MDS (P = .001).
  • Five-year probability of relapse was 9%, 22%, 24%, 56%, and 53%, respectively (P < .001).
  • In multivariate analysis, WHO classification showed a significant effect on OS (P = .017) and probability of relapse (P = .01); transfusion dependency was associated with a reduced OS (P = .01) and increased TRM (P = .037), whereas WPSS showed a prognostic significance on both OS (P = .001) and probability of relapse (P < .001).

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18497321.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Levis A; Rambaldi A; Bandini G; Casini M; Rossi G; Angelucci E; Baronciani D; La Nasa G; Milone G; Mordini N; Guidi S; Bosi A; Bacigalupo A; Van Lint MT; Corradini P; Milani R; Morra E; Marenco P; Lambretenghi Deliliers G; Onida F; Ciceri F; Bernardi M; Castagna L; Narni F; Pioltelli P; Selleri C; Scimè R; Iannitto E; Musso M; Alessandrino EP; Locatelli F; Martelli F; Visani G; Di Bartolomeo P; Cavanna L; Papineschi F; Messina G; Gugliotta L; Iori AP; Foà R; Locasciulli A; Majolino I; Chiusolo P; Leone G; Arcese W; Cerretti R; Carella AM; Cascavilla N; Mazza P; Falda M; Bruno B; Boccadoro M; Fanin R; Cerno M; Raimondi R
  •  go-up   go-down


62. Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV, Ancliff P, Morgan M, Masurekar A, Goulden N, Green N, Révész T, Darbyshire P, Love S, Saha V: Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet; 2010 Dec 11;376(9757):2009-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
  • BACKGROUND: Although survival of children with acute lymphoblastic leukaemia has improved greatly in the past two decades, the outcome of those who relapse has remained static.
  • We investigated the outcome of children with acute lymphoblastic leukaemia who relapsed on present therapeutic regimens.
  • Patients aged 1-18 years with first relapse of acute lymphoblastic leukaemia were stratified into high-risk, intermediate-risk, and standard-risk groups on the basis of duration of first complete remission, site of relapse, and immunophenotype.
  • Differences in progression-free survival between groups were mainly related to a decrease in disease events (progression, second relapse, disease-related deaths; HR 0·56, 0·34-0·92, p=0·007) rather than an increase in adverse treatment effects (treatment death, second malignancy; HR 0·52, 0·24-1·11, p=0·11).
  • INTERPRETATION: As compared with idarubicin, mitoxantrone conferred a significant benefit in progression-free and overall survival in children with relapsed acute lymphobastic leukaemia, a potentially useful clinical finding that warrants further investigation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Idarubicin / therapeutic use. Mitoxantrone / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Blood. 2008 Mar 1;111(5):2548-55 [18039957.001]
  • [Cites] J Clin Oncol. 2007 Dec 20;25(36):5800-7 [18089878.001]
  • [Cites] J Cell Mol Med. 2009 Oct;13(10):4239-56 [19725919.001]
  • [Cites] J Clin Oncol. 2010 May 10;28(14):2339-47 [20385996.001]
  • [Cites] Leukemia. 2010 Feb;24(2):253-4 [20145664.001]
  • [Cites] Leukemia. 2010 Feb;24(2):450-9 [20016529.001]
  • [Cites] J Clin Oncol. 2010 Feb 1;28(4):648-54 [19841326.001]
  • [Cites] Cell Mol Immunol. 2009 Dec;6(6):469-75 [20003823.001]
  • [Cites] Curr Oncol Rep. 2008 Nov;10(6):453-8 [18928659.001]
  • [Cites] J Clin Oncol. 2008 Aug 20;26(24):3971-8 [18711187.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2573-80 [18089849.001]
  • [Cites] Br J Haematol. 2000 Mar;108(3):531-43 [10759711.001]
  • [Cites] Br J Haematol. 2002 Sep;118(3):741-7 [12181040.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1270-6 [12406912.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1013-34 [12764363.001]
  • [Cites] Semin Radiat Oncol. 2003 Jul;13(3):176-81 [12903007.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Feb;53(2):155-62 [14504921.001]
  • [Cites] J Biol Chem. 2004 Apr 30;279(18):18814-23 [14963025.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 20;96(20):1495-6 [15494596.001]
  • [Cites] J Clin Oncol. 1985 Jul;3(7):998-1004 [3860629.001]
  • [Cites] Cancer Res. 1990 Oct 15;50(20):6525-8 [2208112.001]
  • [Cites] Blood. 1991 Sep 1;78(5):1166-72 [1878583.001]
  • [Cites] Int J Hematol. 1991 Jun;54(3):219-30 [1747457.001]
  • [Cites] Haematologica. 1997 Nov-Dec;82(6):664-7 [9499665.001]
  • [Cites] N Engl J Med. 1998 Jun 4;338(23):1663-71 [9614257.001]
  • [Cites] Clin Exp Immunol. 2005 Jan;139(1):152-8 [15606626.001]
  • [Cites] Health Aff (Millwood). 2005 Jan-Feb;24(1):67-78 [15647217.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):67-75 [15982346.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7942-50 [16258094.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2130-8 [16304572.001]
  • [CommentIn] Lancet. 2010 Dec 11;376(9757):1968-70 [21131040.001]
  • [CommentIn] Nat Rev Clin Oncol. 2011 Mar;8(3):123 [21480558.001]
  • (PMID = 21131038.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 14840; United Kingdom / Cancer Research UK / /
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 04079A1RDZ / Cytarabine; 30IQX730WE / Polyethylene Glycols; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7D96IR0PPM / pegaspargase; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; YL5FZ2Y5U1 / Methotrexate; ZRP63D75JW / Idarubicin
  • [Other-IDs] NLM/ PMC3010035
  •  go-up   go-down


63. Bastida Vilá P, Palacio García C, Solsona Riera M, Ortega Aramburu JJ, Sánchez de Toledo Codina J: [Minimal residual disease in acute lymphoblastic leukemia: a new concept of complete remission]. An Pediatr (Barc); 2005 Nov;63(5):390-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Minimal residual disease in acute lymphoblastic leukemia: a new concept of complete remission].
  • INTRODUCTION: Early response to induction treatment is one of the most important prognostic factors in children with acute lymphoblastic leukemia (ALL).
  • Cytological remission is currently achieved in 95-98 % of these patients, although a significant proportion will later relapse.
  • More sensitive techniques are required to measure residual leukemia and establish a new definition of complete remission.
  • [MeSH-major] Neoplasm, Residual / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16266612.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


64. Atalay B, Altinörs N, Yilmaz C, Koçbiyik A: Extraaxial chloroma of the cerebellopontine angle: case report. Turk Neurosurg; 2007 Oct;17(4):286-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A chloroma or granulocytic sarcoma is an extramedullary leukemia.
  • We present an 8-year old patient with an extraaxial chloroma of the cerebellopontine angle to highlight this very rare and malignant pathology in the differential diagnosis of cerebellopontine angle tumors.
  • The presented case, being the fourth chloroma in the cerebellopontine angle, occurred in the absence of relapse which is very unusual for these lesions.
  • Chloroma should be remembered as a very rare and a malignant pathology in the differential diagnosis of pediatric cerebellopontine angle tumors.
  • [MeSH-minor] Cerebellum / pathology. Child. Fatal Outcome. Female. Humans. Leukemia, Myeloid, Acute / complications. Magnetic Resonance Imaging. Neurosurgical Procedures. Unconsciousness / complications

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18050075.001).
  • [ISSN] 1019-5149
  • [Journal-full-title] Turkish neurosurgery
  • [ISO-abbreviation] Turk Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


65. Wang ZD, Qin YZ, Liu YR, Xu LP, Liu DH, Liu KY, Huang XJ: [Monitoring AML1-ETO mRNA levels by real-time quantitative RT-PCR in t(8;21) acute myeloid leukemia patients after hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi; 2008 Oct;29(10):672-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Monitoring AML1-ETO mRNA levels by real-time quantitative RT-PCR in t(8;21) acute myeloid leukemia patients after hematopoietic stem cell transplantation].
  • OBJECTIVE: To evaluate the value of real time quantitative RT-PCR (Q-PCR) for monitoring AML1-ETO mRNA levels in AML1-ETO(+) acute myeloid leukemia (AML) patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT).
  • The AML1-ETO mRNA levels in one relapsed patient were 0, 9.8 and 5.6 at +1, +2 and +3 month post allo-HSCT, respectively and hematological relapse occurred at +110 day, when the AML1-ETO mRNA levels increased dramatically from 5.600 to 390.000.
  • Persistence of a low level within one year after allo-HSCT does not mean at risk of relapse.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / metabolism. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / metabolism. Oncogene Proteins, Fusion / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19176061.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger
  •  go-up   go-down


66. Rogers PC, Meacham LR, Oeffinger KC, Henry DW, Lange BJ: Obesity in pediatric oncology. Pediatr Blood Cancer; 2005 Dec;45(7):881-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A recent Children's Oncology Group symposium considered epidemiology of obesity, pharmacology of chemotherapy and outcomes in obese adults with cancer, excess mortality in obese pediatric patients with acute myeloid leukemia (AML), and complications in obese survivors.
  • In pediatric acute myeloblastic leukemia, obese patients have greater treatment-related mortality (TRM), similar toxicity and relapse rates, and inferior survival compared with patients who are not obese.
  • An excess of female survivors of childhood leukemia who received cranial irradiation are obese.
  • [MeSH-major] Leukemia, Myeloid, Acute. Obesity. Precursor Cell Lymphoblastic Leukemia-Lymphoma


67. Schmid C, Schleuning M, Hentrich M, Markl GE, Gerbitz A, Tischer J, Ledderose G, Oruzio D, Hiddemann W, Kolb HJ: High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission. Bone Marrow Transplant; 2008 Apr;41(8):721-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission.
  • Two-year cumulative incidences for relapse and nonrelapse mortality (NRM) were 4.6 and 22.5%, respectively.
  • Four-year overall and leukemia-free survival was 72.7% (median follow-up among survivors: 35 months).
  • Survival and cumulative incidences of relapse and NRM were identical in both groups.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Transplantation Conditioning / methods


68. Becton D, Dahl GV, Ravindranath Y, Chang MN, Behm FG, Raimondi SC, Head DR, Stine KC, Lacayo NJ, Sikic BI, Arceci RJ, Weinstein H, Pediatric Oncology Group: Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood; 2006 Feb 15;107(4):1315-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Relapse is a major obstacle in the cure of acute myeloid leukemia (AML).

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Aug 1;94(3):1086-99 [10419902.001]
  • [Cites] N Engl J Med. 1999 Sep 30;341(14):1051-62 [10502596.001]
  • [Cites] Int J Clin Pharmacol Ther. 2000 Mar;38(3):94-110 [10739113.001]
  • [Cites] J Clin Oncol. 2000 May;18(9):1867-75 [10784627.001]
  • [Cites] Blood. 2000 Jul 1;96(1):365-8 [10891476.001]
  • [Cites] Blood. 2001 Jan 1;97(1):56-62 [11133742.001]
  • [Cites] Curr Oncol Rep. 2000 Nov;2(6):529-38 [11122889.001]
  • [Cites] Leukemia. 2001 Mar;15(3):348-54 [11237056.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2705-13 [11352963.001]
  • [Cites] Best Pract Res Clin Haematol. 2001 Mar;14(1):211-33 [11355932.001]
  • [Cites] Best Pract Res Clin Haematol. 2001 Mar;14(1):95-118 [11355926.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3605-11 [11369657.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5461-7 [11454692.001]
  • [Cites] Cell Mol Life Sci. 2001 Jun;58(7):931-59 [11497241.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3212-20 [11719356.001]
  • [Cites] Leukemia. 2002 May;16(5):833-9 [11986944.001]
  • [Cites] Leukemia. 2002 May;16(5):920-7 [11986955.001]
  • [Cites] J Histochem Cytochem. 1977 Jul;25(7):935-41 [894009.001]
  • [Cites] Blood. 1980 Jun;55(6):960-8 [6966518.001]
  • [Cites] Cancer Res. 1991 Sep 1;51(17):4665-70 [1873811.001]
  • [Cites] J Clin Oncol. 1992 Oct;10(10):1635-42 [1403041.001]
  • [Cites] Leukemia. 1994 Sep;8(9):1492-7 [7916390.001]
  • [Cites] Hematol Oncol Clin North Am. 1995 Apr;9(2):363-82 [7642468.001]
  • [Cites] Blood. 1995 Sep 15;86(6):2329-42 [7545025.001]
  • [Cites] Leukemia. 1995 Dec;9(12):2042-8 [8609715.001]
  • [Cites] N Engl J Med. 1996 May 30;334(22):1428-34 [8618581.001]
  • [Cites] Blood. 1996 Jun 1;87(11):4809-16 [8639853.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3010-20 [8674056.001]
  • [Cites] Blood. 1996 Oct 15;88(8):2841-51 [8874180.001]
  • [Cites] Blood. 1997 May 1;89(9):3323-9 [9129038.001]
  • [Cites] Lancet. 1998 Mar 7;351(9104):700-8 [9504514.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):872-81 [9508168.001]
  • [Cites] Leuk Lymphoma. 1998 Jan;28(3-4):315-27 [9517503.001]
  • [Cites] Br J Haematol. 1998 Apr;101(1):130-40 [9576193.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4116-24 [10361108.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1046-56 [10419897.001]
  • [CommentIn] Blood. 2006 Jun 15;107(12):4975-6; author reply 4976-7 [16754781.001]
  • (PMID = 16254147.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA90916
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / P-Glycoprotein; 094ZI81Y45 / Tamoxifen; 80168379AG / Doxorubicin; 83HN0GTJ6D / Cyclosporine; LJ2P1SIK8Y / Mitolactol
  • [Other-IDs] NLM/ PMC1895393
  •  go-up   go-down


69. Kim SY, Lee DG, Kim MS, Kim HJ, Lee S, Min CK: The influence of infection early after allogeneic stem cell transplantation on the risk of leukemic relapse and graft-versus-host disease. Am J Hematol; 2008 Oct;83(10):784-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of infection early after allogeneic stem cell transplantation on the risk of leukemic relapse and graft-versus-host disease.
  • Further, a post-SCT infection may influence the milieu of the graft-versus-leukemia (GVL) effect and graft-versus-host disease (GVHD).
  • We performed a retrospective study of patients with acute leukemia who had undergone allogeneic SCT using the same preparative regimens and bone marrow as the stem cell source to determine if early post-transplant infection was associated with the risk of leukemic relapse and GVHD.
  • The analysis revealed that patients who had a febrile infection (FI) before post-transplant day 21 (FI group) had a lower actuarial probability of leukemic relapse (P < 0.001) and a higher relapse-free survival rate (P = 0.012) than those patients who did not have a FI before post-transplant day 21 (non-FI group).
  • The experience of early post-transplant FI (HR = 0.316; 95% CI = 0.174-0.575; P < 0.001), together with the presence of chronic GVHD and high risk cytogenetics, were independent predictive factors for post-transplant leukemic relapse.
  • [MeSH-major] Graft vs Host Disease / immunology. Graft vs Host Disease / prevention & control. Infection / immunology. Leukemia / immunology. Stem Cell Transplantation
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Female. Graft vs Leukemia Effect / immunology. Humans. Male. Middle Aged. Retrospective Studies. Risk Factors. Secondary Prevention. Time Factors. Transplantation, Homologous / immunology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • (PMID = 18661492.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Nakasone H, Kida M, Iki S, Usuki K: Lower leukocytes at initial diagnosis may predict poor outcome of very late relapse of acute lymphoblastic leukemia. Leuk Res; 2008 Apr;32(4):659-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lower leukocytes at initial diagnosis may predict poor outcome of very late relapse of acute lymphoblastic leukemia.
  • We have reported a rare case of acute lymphoblastic leukemia (ALL) recurring 19 years after the first presentation.
  • Since 1984, 36 relapse cases 10 years or more after the first diagnosis have been reported.
  • A very late relapse of ALL remains chemosensitive, and its prognosis is not unfavorable.
  • [MeSH-major] Neoplasm Recurrence, Local / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17850867.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


71. Asou N, Yanagida M, Huang L, Yamamoto M, Shigesada K, Mitsuya H, Ito Y, Osato M: Concurrent transcriptional deregulation of AML1/RUNX1 and GATA factors by the AML1-TRPS1 chimeric gene in t(8;21)(q24;q22) acute myeloid leukemia. Blood; 2007 May 1;109(9):4023-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent transcriptional deregulation of AML1/RUNX1 and GATA factors by the AML1-TRPS1 chimeric gene in t(8;21)(q24;q22) acute myeloid leukemia.
  • The Runt domain transcription factor AML1/RUNX1 is essential for the generation of hematopoietic stem cells and is the most frequent target of chromosomal translocations associated with leukemia.
  • Here, we present a new AML1 translocation found in a patient with acute myeloid leukemia M4 with t(8;21)(q24;q22) at the time of relapse.
  • [MeSH-major] Cell Transformation, Neoplastic / metabolism. Core Binding Factor Alpha 2 Subunit / biosynthesis. DNA-Binding Proteins / biosynthesis. GATA Transcription Factors / metabolism. Leukemia, Myeloid, Acute / metabolism. Oncogene Proteins, Fusion / biosynthesis. Transcription Factors / biosynthesis

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17244685.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / DNA-Binding Proteins; 0 / GATA Transcription Factors; 0 / Oncogene Proteins, Fusion; 0 / RUNX1 protein, human; 0 / TRPS1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


72. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, Marsh SG, Geraghty D, Spellman S, Haagenson MD, Ladner M, Trachtenberg E, Parham P, Miller JS: Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood; 2010 Oct 7;116(14):2411-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia.
  • We KIR genotyped donors from 1409 unrelated transplants for acute myelogenous leukemia (AML; n = 1086) and acute lymphoblastic leukemia (ALL; n = 323).
  • Compared with A haplotype motifs, centromeric and telomeric B motifs both contributed to relapse protection and improved survival, but Cen-B homozygosity had the strongest independent effect.
  • With Cen-B/B homozygous donors the cumulative incidence of relapse was 15.4% compared with 36.5% for Cen-A/A donors (relative risk of relapse 0.34; 95% confidence interval 0.2-0.57; P < .001).
  • Overall, significantly reduced relapse was achieved with donors having 2 or more B gene-content motifs (relative risk 0.64; 95% confidence interval 0.48-0.86; P = .003) for both HLA-matched and mismatched transplants.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Aug 1;102(3):814-9 [12689936.001]
  • [Cites] Br J Haematol. 2003 Oct;123(2):323-6 [14531915.001]
  • [Cites] Crit Rev Immunol. 2002;22(5-6):463-82 [12803322.001]
  • [Cites] J Immunol. 2004 Jan 1;172(1):644-50 [14688377.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1521-6 [14504099.001]
  • [Cites] Tissue Antigens. 2004 Mar;63(3):204-11 [14989709.001]
  • [Cites] Gene. 2004 Jun 23;335:121-31 [15194195.001]
  • [Cites] Science. 2004 Aug 6;305(5685):872-4 [15297676.001]
  • [Cites] N Engl J Med. 1989 Jun 29;320(26):1731-5 [2543925.001]
  • [Cites] Immunol Today. 1990 Jul;11(7):237-44 [2201309.001]
  • [Cites] Blood. 1993 Oct 15;82(8):2577-84 [8400305.001]
  • [Cites] Science. 1995 Apr 21;268(5209):405-8 [7716543.001]
  • [Cites] Immunity. 1995 May;2(5):439-49 [7749980.001]
  • [Cites] Immunity. 1997 Dec;7(6):739-51 [9430220.001]
  • [Cites] Immunity. 1997 Dec;7(6):753-63 [9430221.001]
  • [Cites] J Immunol. 1998 Jul 15;161(2):571-7 [9670929.001]
  • [Cites] Nat Rev Immunol. 2005 Mar;5(3):201-14 [15719024.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4878-84 [15731175.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13224-9 [16141329.001]
  • [Cites] Immunogenetics. 2006 Aug;58(8):614-27 [16823588.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Aug;12(8):828-36 [16864053.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Aug;12(8):876-84 [16864058.001]
  • [Cites] Bone Marrow Transplant. 2006 Sep;38(6):437-44 [16892071.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3603-6 [17179231.001]
  • [Cites] Hum Immunol. 2007 May;68(5):309-23 [17462498.001]
  • [Cites] Immunogenetics. 2007 Jul;59(7):525-37 [17464504.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4246-54 [17724349.001]
  • [Cites] Stat Med. 2007 Oct 30;26(24):4505-19 [17348080.001]
  • [Cites] Tissue Antigens. 2007 Dec;70(6):449-54 [17900289.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4576-83 [17785583.001]
  • [Cites] J Immunol. 2008 Mar 15;180(6):3969-79 [18322206.001]
  • [Cites] Blood. 2008 Aug 1;112(3):461-9 [18650461.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2369-80 [18583565.001]
  • [Cites] Blood. 2009 Jan 15;113(3):726-32 [18945962.001]
  • [Cites] Blood. 2009 Mar 26;113(13):3110-8 [19059878.001]
  • [Cites] Trends Immunol. 2009 Apr;30(4):143-9 [19282243.001]
  • [Cites] JAMA. 2009 Jun 10;301(22):2349-61 [19509382.001]
  • [Cites] Biol Blood Marrow Transplant. 2010 Apr;16(4):533-42 [19961944.001]
  • [Cites] Blood. 2010 Apr 15;115(15):3162-5 [20124216.001]
  • [Cites] Biol Blood Marrow Transplant. 2010 Sep;16(9):1257-64 [20302958.001]
  • [Cites] J Immunol. 2002 Jan 1;168(1):240-52 [11751968.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4778-83 [10781084.001]
  • [Cites] Blood. 2001 Oct 1;98(7):2043-51 [11567988.001]
  • [Cites] N Engl J Med. 2001 Dec 20;345(25):1794-800 [11752355.001]
  • [Cites] Annu Rev Immunol. 2002;20:323-70 [11861606.001]
  • [Cites] Science. 2002 Mar 15;295(5562):2097-100 [11896281.001]
  • [Cites] J Immunol. 2002 Jul 1;169(1):239-47 [12077250.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3825-7 [12393440.001]
  • [CommentIn] Blood. 2010 Oct 7;116(14):2407-9 [20930082.001]
  • [CommentIn] Nat Rev Clin Oncol. 2011 Jan;8(1):3 [21218525.001]
  • (PMID = 20581313.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / 5U01HL069294; United States / NCI NIH HHS / CA / P01 CA065493; United States / NCI NIH HHS / CA / U24 CA076518; United States / PHS HHS / / HHSH234200637015C; United States / NCI NIH HHS / CA / U24-CA76518; United States / NHLBI NIH HHS / HL / U01 HL069294; United States / PHS HHS / / P01 111412
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, KIR
  • [Other-IDs] NLM/ PMC2953880
  •  go-up   go-down


73. Callens C, Chevret S, Cayuela JM, Cassinat B, Raffoux E, de Botton S, Thomas X, Guerci A, Fegueux N, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Ferrand A, Sanz M, Chomienne C, Fenaux P, Dombret H, European APL Group: Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. Leukemia; 2005 Jul;19(7):1153-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group.
  • If FLT3-ITD is associated with a worse outcome in patients with acute myeloid leukemia (AML) in general, its prognostic value in acute promyelocytic leukemia (APL) is still a matter of debate.
  • Complete remission (CR), induction death, and death in CR rates were not affected by FLT3 or Ras mutations, as well as cumulative incidence of relapse.
  • This feature, which has been also reported in patients with AML in general, is suggestive of an underlying genetic instability in FLT3-ITD patients, leading to the acquisition of additional unknown bad-prognosis gene mutations at relapse.
  • [MeSH-major] Genes, ras / genetics. Leukemia, Promyelocytic, Acute / genetics. Proto-Oncogene Proteins / genetics. Receptor Protein-Tyrosine Kinases / genetics

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15889156.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


74. Knipp S, Gattermann N, Schapira M, Käferstein H, Germing U: Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement. Leuk Res; 2007 Nov;31(11):1585-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
  • We report on a 42-year-old patient whose relapse of acute promyelocytic leukaemia (APL) included meningeal infiltration.
  • ATO thus crosses the blood-CSF-barrier when administered intravenously, but the concentration in CSF is probably not sufficient for treatment of meningeal leukemia.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Arsenic / cerebrospinal fluid. Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17416415.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; N712M78A8G / Arsenic; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


75. Pritchard MT, Butow PN, Stevens MM, Duley JA: Understanding medication adherence in pediatric acute lymphoblastic leukemia: a review. J Pediatr Hematol Oncol; 2006 Dec;28(12):816-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Understanding medication adherence in pediatric acute lymphoblastic leukemia: a review.
  • Significant numbers of children and adolescents with acute lymphoblastic leukemia (ALL) do not adequately adhere to their treatment regimen.
  • Failure to take the appropriate amount of prescribed medication may result in disease relapse.
  • [MeSH-major] Patient Compliance. Patient Education as Topic. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164651.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 61
  •  go-up   go-down


76. Takahashi T, Tsukuda H, Kimura H, Yoshimoto M, Tsujisaki M: Extramedullary relapse of AML with t(9;11)(p22;q23) associated with clonal evolution from trisomy 8 into tetrasomy 8. Intern Med; 2010;49(5):447-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramedullary relapse of AML with t(9;11)(p22;q23) associated with clonal evolution from trisomy 8 into tetrasomy 8.
  • This report describes a patient with extramedullary relapse of acute myeloid leukemia (AML) without involving bone marrow.
  • A 57-year-old man was diagnosed as having acute monoblastic leukemia with t(9;11)(p22;q23) and trisomy 8.
  • Aspiration from the forearm showed leukemic relapse, and fluorescence in situ hybridization (FISH) revealed that the majority of the cells had 11q23 anomaly and tetrasomy 8.
  • Bone marrow or meningeal relapse was not observed.
  • To our knowledge, this is the first case report of clonal evolution associated with the development of myeloid sarcoma as a relapse in AML.
  • [MeSH-major] Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 8 / genetics. Chromosomes, Human, Pair 9 / genetics. Leukemia, Myeloid, Acute / genetics. Sarcoma, Myeloid / diagnosis. Sarcoma, Myeloid / genetics. Trisomy / genetics

  • Genetic Alliance. consumer health - Chromosome 9, Trisomy.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20190481.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


77. Conkright MD, Montminy M: CREB: the unindicted cancer co-conspirator. Trends Cell Biol; 2005 Sep;15(9):457-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A new report by Shankar et al. shows that patients with acute myeloid leukemia (AML) have a greater incidence of relapse when intracellular levels of CREB are elevated.
  • [MeSH-minor] Animals. Cell Proliferation. Cell Survival / physiology. Gene Expression Regulation, Leukemic / genetics. Humans. Leukemia, Myeloid / genetics. Leukemia, Myeloid / pathology. Mice. Mice, Transgenic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16084096.001).
  • [ISSN] 0962-8924
  • [Journal-full-title] Trends in cell biology
  • [ISO-abbreviation] Trends Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclic AMP Response Element-Binding Protein
  • [Number-of-references] 15
  •  go-up   go-down


78. Gaynon PS, Harris RE, Altman AJ, Bostrom BC, Breneman JC, Hawks R, Steele D, Zipf T, Stram DO, Villaluna D, Trigg ME: Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941. J Clin Oncol; 2006 Jul 1;24(19):3150-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941.
  • PURPOSE: To compare conventional sibling bone marrow transplantation (CBMT), BMT with alternative donor (ABMT), and chemotherapy (CT) for children with acute lymphoblastic leukemia (ALL) and an early first marrow relapse.
  • PATIENTS AND METHODS: After informed consent, 214 patients with ALL and early marrow relapse began multiagent induction therapy.
  • Outcomes remain similar and poor for children with ALL and early marrow relapse.
  • BMT is not a complete answer to the challenge of ALL and early marrow relapse.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Neoplasms / surgery. Bone Marrow Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery


79. Aoki T, Miyamoto T, Yoshida S, Yamamoto A, Yamauchi T, Yoshimoto G, Mori Y, Kamezaki K, Iwasaki H, Takenaka K, Harada N, Nagafuji K, Teshima T, Akashi K: Additional acquisition of t(1;21)(p32;q22) in a patient relapsing with acute myelogenous leukemia with NUP98-HOXA9. Int J Hematol; 2008 Dec;88(5):571-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Additional acquisition of t(1;21)(p32;q22) in a patient relapsing with acute myelogenous leukemia with NUP98-HOXA9.
  • We report a 29-year-old Japanese male with acute myelogenous leukemia (AML)-M4 with a cryptic t(7;11)(p15;p15), in which a chimeric NUP98-HOXA9 fusion was detected by polymerase chain reaction analysis and a chromosomal analysis showed 46,XY.
  • This is the first reported case with AML who had a cryptic t(7;11)(p15;p15), and additionally acquired t(1;21)(p32;q22) at relapse.
  • [MeSH-major] Chromosomes, Human / genetics. Core Binding Factor Alpha 2 Subunit / genetics. Homeodomain Proteins / genetics. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / therapy. Nuclear Pore Complex Proteins / genetics. Oncogene Proteins, Fusion / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1992 Mar;6(3):232 [1564964.001]
  • [Cites] Int J Hematol. 2006 Aug;84(2):136-42 [16926135.001]
  • [Cites] Blood. 1998 Jul 15;92(2):574-88 [9657758.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Sep;129(2):155-60 [11566347.001]
  • [Cites] Bone Marrow Transplant. 1997 Nov;20(10):821-6 [9404921.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11781-91 [17178874.001]
  • [Cites] Nat Genet. 1996 Feb;12(2):159-67 [8563754.001]
  • [Cites] Blood. 2005 Jan 15;105(2):784-93 [15454493.001]
  • [Cites] Cancer Invest. 2003;21(1):105-36 [12643014.001]
  • [Cites] Curr Opin Hematol. 2005 May;12(3):210-6 [15867577.001]
  • [Cites] Br J Haematol. 1997 Mar;96(4):682-7 [9074407.001]
  • [Cites] Oncogene. 2008 Jun 19;27(27):3765-79 [18264136.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1532-42 [12176867.001]
  • [Cites] Ann N Y Acad Sci. 2007 Jun;1106:114-42 [17442773.001]
  • [Cites] Blood. 2002 Jan 1;99(1):310-8 [11756186.001]
  • [Cites] Am J Hematol. 1994 Sep;47(1):62-4 [8042621.001]
  • [Cites] Haematologica. 2007 Jun;92(6):861-2 [17550866.001]
  • [Cites] Br J Haematol. 1999 Dec;107(3):600-4 [10583265.001]
  • [Cites] EMBO J. 2001 Feb 1;20(3):350-61 [11157742.001]
  • [Cites] Leukemia. 2001 Nov;15(11):1689-95 [11681408.001]
  • [Cites] Haematologica. 1997 May-Jun;82(3):364-70 [9234595.001]
  • (PMID = 19005624.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Homeodomain Proteins; 0 / NUP98-HOXA9 fusion protein, human; 0 / Nuclear Pore Complex Proteins; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


80. Wojnar J, Giebel S, Hołowiecka-Goral A, Krawczyk-Kuliś M, Markiewicz M, Stella-Hołowiecka B, Wylezoł I: [Impact of chronic graft-versus-host disease on long-term outcome after allogeneic hematopoietic cell transplantation in adult acute lymphoblastic leukemia]. Pol Arch Med Wewn; 2006 Jul;116(1):671-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of chronic graft-versus-host disease on long-term outcome after allogeneic hematopoietic cell transplantation in adult acute lymphoblastic leukemia].
  • However, it may be accompanied by graft-versus-leukemia (GVL) reaction contributing to decreased risk of relapse.
  • The aim of this study was to evaluate the influence of cGVHD on outcome of adult acute lymphoblastic leukemia (ALL) patients treated with alloHCT.
  • Cumulative incidence of relapse and non-relapse mortality (NRM) was 39% and 13%, respectively.
  • In the respective subgroups relapse incidence was 60%, 9% and 0%, whereas the incidence of NRM equaled 3%, 6% and 62%.
  • In multivariate analysis the lack of cGVHD was the most important factor associated with increased risk of relapse and deteriorated DFS.
  • Induction of limited cGVHD may constitute the most effective prophylaxis of relapse in this group of patients.
  • [MeSH-major] Graft vs Host Disease / epidemiology. Graft vs Leukemia Effect. Hematopoietic Stem Cell Transplantation / statistics & numerical data. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


81. Ehlers S, Herbst C, Zimmermann M, Scharn N, Germeshausen M, von Neuhoff N, Zwaan CM, Reinhardt K, Hollink IH, Klusmann JH, Lehrnbecher T, Roettgers S, Stary J, Dworzak M, Welte K, Creutzig U, Reinhardt D: Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse. J Clin Oncol; 2010 May 20;28(15):2591-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse.
  • PURPOSE: This prospective, multicenter Acute Myeloid Leukemia Berlin-Frankfurt-Muenster (AML-BFM) 98 study randomly tested the ability of granulocyte colony-stimulating factor (G-CSF) to reduce infectious complications and to improve outcomes in children and adolescents with acute myeloid leukemia (AML).
  • RESULTS: In patients randomly assigned to receive G-CSF after induction, 16 patients overexpressing the G-CSFR isoform IV showed an increased 5-year cumulative incidence of relapse (50% +/- 13%) compared with 14 patients with low-level isoform IV expression (14% +/- 10%; log-rank P = .04).
  • Multivariate analyses of the G-CSF-treated subgroup, including the parameters G-CSFR isoform IV overexpression, sex, and favorable cytogenetics as covariables, revealed the prognostic relevance of G-CSFR isoform IV overexpression for 5-year event-free survival (P = .031) and the 5-year cumulative incidence of relapse (P = .049).
  • CONCLUSION: Our results demonstrate that children and adolescents with AMLs that overexpress the differentiation-defective G-CSFR isoform IV respond to G-CSF administration after induction, but with a significantly higher incidence of relapse.
  • [MeSH-major] Granulocyte Colony-Stimulating Factor / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Receptors, Granulocyte Colony-Stimulating Factor / biosynthesis


82. Jegalian AG, Buxbaum NP, Facchetti F, Raffeld M, Pittaluga S, Wayne AS, Jaffe ES: Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica; 2010 Nov;95(11):1873-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nine patients were alive 5 years after the original diagnosis, although only three of them had undergone hematopoietic stem cell transplantation--one in first complete remission and two in second remission.
  • Of the seven patients who lacked cutaneous disease at presentation, 100% survived, including five who were alive more than 5 years after diagnosis, although only two had undergone stem cell transplantation.
  • S-100 was negative in 28 cases of acute myeloid leukemia evaluated for this marker.
  • Treatment with high-risk acute lymphoblastic leukemia-type chemotherapy appears to be effective, and stem cell transplantation may be reserved for children who relapse and achieve a second remission.

  • Genetic Alliance. consumer health - Blastic Plasmacytoid Dendritic Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Dec 1;165(11):6037-46 [11086035.001]
  • [Cites] Br J Dermatol. 2010 Jan;162(1):74-9 [19689477.001]
  • [Cites] Blood. 2001 May 15;97(10):3210-7 [11342451.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1556-63 [11861268.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):852-62 [12131152.001]
  • [Cites] Leuk Res. 2002 Sep;26(9):803-7 [12127554.001]
  • [Cites] Blood. 2003 Jun 15;101(12):5007-9 [12576313.001]
  • [Cites] Eur J Haematol. 2003 Oct;71(4):294-8 [12950240.001]
  • [Cites] Bone Marrow Transplant. 2003 Oct;32(7):637-46 [13130309.001]
  • [Cites] Am J Surg Pathol. 2003 Oct;27(10):1366-74 [14508398.001]
  • [Cites] Eur J Immunol. 2004 Feb;34(2):418-26 [14768046.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1097-108 [15205205.001]
  • [Cites] Am J Clin Pathol. 2004 Aug;122(2):307-13 [15323148.001]
  • [Cites] Diagn Mol Pathol. 1992 Sep;1(3):173-9 [1342963.001]
  • [Cites] Ann Intern Med. 1999 Oct 5;131(7):549-50 [10507983.001]
  • [Cites] Nat Immunol. 2004 Dec;5(12):1219-26 [15549123.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1256-64 [15388576.001]
  • [Cites] J Korean Med Sci. 2005 Apr;20(2):319-24 [15832009.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):662-75 [15981806.001]
  • [Cites] Am J Surg Pathol. 2005 Oct;29(10):1274-83 [16160468.001]
  • [Cites] Leuk Lymphoma. 2006 Apr;47(4):715-25 [16690531.001]
  • [Cites] Haematologica. 2006 Dec;91(12 Suppl):ECR48 [17194654.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1720-7 [17068154.001]
  • [Cites] Am J Clin Pathol. 2007 May;127(5):687-700 [17439829.001]
  • [Cites] Am J Clin Pathol. 2007 Sep;128(3):445-53 [17709319.001]
  • [Cites] Haematologica. 2007 Sep;92(9):e91-3 [17768139.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 Nov;29(11):766-9 [17984695.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3778-92 [18218851.001]
  • [Cites] Immunity. 2008 Sep 19;29(3):352-61 [18799143.001]
  • [Cites] Blood. 2009 Apr 9;113(15):3418-27 [19176316.001]
  • [Cites] Science. 2009 Apr 17;324(5925):392-7 [19286519.001]
  • [Cites] J Pediatr Hematol Oncol. 2009 May;31(5):339-43 [19415013.001]
  • [Cites] Br J Haematol. 2009 Jun;145(5):624-36 [19388928.001]
  • [Cites] Cytometry B Clin Cytom. 2009 Jul;76(4):237-48 [19382197.001]
  • [Cites] Adv Anat Pathol. 2009 Nov;16(6):392-404 [19851130.001]
  • [Cites] Am J Surg Pathol. 2010 Jan;34(1):75-87 [19956058.001]
  • [Cites] Leuk Res. 2010 Apr;34(4):438-46 [19793612.001]
  • [Cites] Am J Surg Pathol. 2010 Mar;34(3):405-17 [20154586.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):642-6 [11241229.001]
  • (PMID = 20663945.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins
  • [Other-IDs] NLM/ PMC2966909
  •  go-up   go-down


83. Xu SN, Chen JP, Liu JP, Xia Y: [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis]. Zhong Xi Yi Jie He Xue Bao; 2009 Nov;7(11):1024-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
  • BACKGROUND: The studies have demonstrated that arsenic trioxide (ATO) in combination with all-trans retinoic acid (ATRA) takes effects in treatment of acute promyelocytic leukemia (APL) through different underlying mechanisms.
  • DATA EXTRACTION AND ANALYSIS: Related data concerning complete remission rate, overall survival rate, and disease free survival rate, time to complete remission, relapse rate, mortality and adverse reactions were extracted independently by two reviewers.
  • Compared with ATO monotherapy, ATO plus ATRA could improve time to complete remission and relapse rate of newly diagnosed APL, but could not improve the complete remission rate, disease free survival rate, mortality and liver dysfunction of relapsed APL patients based on meta-analysis and sensitivity analysis.
  • Compared with ATRA monotherapy, ATO plus ATRA shortened the time to complete remission, improved the disease free survival rate and relapse rate, but increased the incidence of edema during the treatment.
  • Compared with chemotherapy with ATO plus ATRA, ATO plus ATRA could improve the complete remission rate, relapse rate, mortality and adverse reactions.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use. Tretinoin / therapeutic use

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19912733.001).
  • [ISSN] 1672-1977
  • [Journal-full-title] Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
  • [ISO-abbreviation] Zhong Xi Yi Jie He Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Meta-Analysis; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


84. Diaz MA, Gonzalez-Vicent M, Ramirez M, Sevilla J, Lassaletta A, Perez A, Madero L: Allogeneic cord blood transplantation in children with hematological malignancies: a long-term follow-up single-center study. Pediatr Hematol Oncol; 2009 Jun;26(4):165-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forty-two consecutive pediatric patients with high-risk leukemia who received cord blood (CB) transplantation at the authors' institution from January 1996 and December 2007 were included in this study.
  • The probability of relapse was 33 +/- 9%.
  • [MeSH-major] Antigens, CD34 / blood. Fetal Blood / transplantation. Leukemia, Myeloid, Acute / surgery. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19437319.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


85. Tickenbrock L, Müller-Tidow C, Berdel WE, Serve H: Emerging Flt3 kinase inhibitors in the treatment of leukaemia. Expert Opin Emerg Drugs; 2006 Mar;11(1):153-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acute myeloid leukaemia (AML) is characterised by the infiltration of the bone marrow with highly proliferative leukaemic cells that stop to differentiate at different stages of myeloid development and carry survival advantages.
  • However, despite this aggressive treatment, many patients relapse and eventually die from the disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Protein Kinase Inhibitors / therapeutic use. fms-Like Tyrosine Kinase 3 / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16503833.001).
  • [ISSN] 1744-7623
  • [Journal-full-title] Expert opinion on emerging drugs
  • [ISO-abbreviation] Expert Opin Emerg Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carbazoles; 0 / Indoles; 0 / Protein Kinase Inhibitors; 0 / Pyrroles; 120685-11-2 / 4'-N-benzoylstaurosporine; 71IA9S35AJ / Semaxinib; DO989GC5D1 / lestaurtinib; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; H88EPA0A3N / Staurosporine
  • [Number-of-references] 112
  •  go-up   go-down


86. Konn ZJ, Martineau M, Bown N, Richards S, Swansbury J, Talley P, Wright SL, Harrison CJ: Cytogenetics of long-term survivors of ETV6-RUNX1 fusion positive acute lymphoblastic leukemia. Genes Chromosomes Cancer; 2010 Mar;49(3):253-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetics of long-term survivors of ETV6-RUNX1 fusion positive acute lymphoblastic leukemia.
  • This study describes the cytogenetics of 33 children with ETV6-RUNX1 positive acute lymphoblastic leukemia (ALL) who had been in continuous complete remission for a minimum of 8.8 years [median event-free survival (EFS) 10.9 years].
  • Interphase fluorescence in situ hybridization (FISH) at diagnosis showed deletion of the second ETV6 signal from all fusion positive cells in 45% of the long-term survivors but in none of the relapsed patients, whereas patients with mixed populations with retained or lost second signals were more frequent among those who had relapsed (69%) than the long-term survivors (21%).
  • It appears that the two groups have some distinguishing cytogenetic features at the time of diagnosis, which may provide pointers to relapse that are worthy of more detailed study.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Gene Fusion. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins c-ets / genetics. Repressor Proteins / genetics. Survivors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19998443.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U137686856
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / ETS translocation variant 6 protein; 0 / Proto-Oncogene Proteins c-ets; 0 / RUNX1 protein, human; 0 / Repressor Proteins
  •  go-up   go-down


87. Bacci G, Longhi A, Forni C, Fabbri N, Briccoli A, Barbieri E, Mercuri M, Balladelli A, Ferrari S, Picci P: Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases. Int J Radiat Oncol Biol Phys; 2007 Feb 1;67(2):505-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At a mean follow-up of 11 years (range, 7-22 years), 9 patients remained continuously disease-free, 10 died from osteosarcoma and 1 died from a third neoplasm (myeloid acute leukemia).
  • However, this later group had an 18% 3-year event-free survival after treatment of relapse vs. 0% in the RIO group.


88. Breitscheidel L, Sahakyan A: Modeling relapse-free survival with time-dependent covariate graft-versus-host disease in patients with acute leukemia. Haematologica; 2006 Mar;91(3):ELT03
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modeling relapse-free survival with time-dependent covariate graft-versus-host disease in patients with acute leukemia.
  • [MeSH-major] Graft vs Host Disease / mortality. Neoplasm Recurrence, Local. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Haematologica. 2005 Oct;90(10):1380-8 [16219575.001]
  • (PMID = 16533736.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] Italy
  •  go-up   go-down


89. Resnick IB, Tsirigotis PD, Shapira MY, Aker M, Bitan M, Samuel S, Abdul-Hai A, Ackerstein A, Or R, Slavin S: ABO incompatibility is associated with increased non-relapse and GVHD related mortality in patients with malignancies treated with a reduced intensity regimen: a single center experience of 221 patients. Biol Blood Marrow Transplant; 2008 Apr;14(4):409-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABO incompatibility is associated with increased non-relapse and GVHD related mortality in patients with malignancies treated with a reduced intensity regimen: a single center experience of 221 patients.
  • In this study, we evaluate: the association between ABO-incompatibility and myeloid engraftment; the incidence and severity of acute and chronic graft-versus-host disease (GVHD); non-relapse mortality (NRM); GVHD-associated mortality, relapse and overall survival (OS).
  • Long-term OS and relapse rate were not different, although we observed a trend for decreased OS during the first year post transplantation in the group of patients with major ABO-incompatibility.
  • [MeSH-minor] Adult. Aged. Female. Humans. Leukemia / therapy. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Myelodysplastic Syndromes / therapy. Recurrence. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342783.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABO Blood-Group System
  •  go-up   go-down


90. Buchholz S, Ganser A: [Hematopoietic stem cell transplantation. Indications, foundations and perspective]. Internist (Berl); 2009 May;50(5):572-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Autologous HSCT is mainly done as part of the primary therapy in multiple myeloma and as part of relapse therapy in malignant lymphoma.
  • In contrast, allogeneic HSCT is predominantly performed in patients with acute leukemias.
  • Risk factors which can predict for poor response to chemotherapy can now be identified in acute myeloid as well as lymphoid leukemia, based on phenotype, cytogenetics, molecular genetics and response to therapy.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Hematopoietic Stem Cell Transplantation / trends. Leukemia / surgery. Multiple Myeloma / surgery

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1988 Jun;108(6):806-14 [3285744.001]
  • [Cites] Br J Haematol. 1987 Dec;67(4):397-406 [3322360.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5183-91 [18768435.001]
  • [Cites] Blood. 2002 Aug 1;100(3):755-60 [12130482.001]
  • [Cites] Bone Marrow Transplant. 2006 Nov;38(10):645-51 [16980994.001]
  • [Cites] Curr Opin Hematol. 2007 Mar;14(2):162-9 [17255794.001]
  • [Cites] Blood. 2008 Aug 1;112(3):903-9 [18519812.001]
  • [Cites] N Engl J Med. 1995 Jan 26;332(4):217-23 [7808487.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2816-25 [15254049.001]
  • [Cites] Blood. 2004 Jul 15;104(2):579-85 [15039286.001]
  • [Cites] Ann Hematol. 2008 Jul;87(7):551-6 [18386010.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3685-91 [11504750.001]
  • [Cites] Bone Marrow Transplant. 2008 Mar;41(5):447-53 [17968326.001]
  • [Cites] Bone Marrow Transplant. 2007 May;39(10):577-88 [17369869.001]
  • [Cites] Blood. 1999 May 15;93(10):3267-75 [10233878.001]
  • [Cites] Bone Marrow Transplant. 2006 Jun;37(11):989-95 [16633362.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2912-9 [15994282.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1532-42 [12176867.001]
  • [Cites] Bone Marrow Transplant. 2002 Dec;30(12 ):899-903 [12476283.001]
  • [Cites] Blood. 1990 Feb 1;75(3):555-62 [2297567.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:123-30 [16304369.001]
  • [Cites] N Engl J Med. 2007 Mar 15;356(11):1110-20 [17360989.001]
  • [Cites] Curr Opin Hematol. 2008 Jul;15(4):279-84 [18536563.001]
  • [Cites] Br J Haematol. 2006 Oct;135(2):158-64 [16939489.001]
  • [Cites] Blood. 2003 Nov 1;102(9):3447-54 [12855572.001]
  • [Cites] Transplantation. 2006 May 27;81(10):1390-7 [16732175.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jan;14(1):67-74 [18158963.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5511-9 [17339419.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4262-9 [17724347.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] Bone Marrow Transplant. 2007 Dec;40(12):1101-14 [17680020.001]
  • [Cites] Blood. 2006 Sep 15;108(6):1809-20 [16709930.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1909-18 [18450602.001]
  • [Cites] Bone Marrow Transplant. 2000 May;25 Suppl 2:S6-8 [10933177.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2667-74 [18621929.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3098-104 [9787144.001]
  • [Cites] Blood. 2007 May 15;109(10):4119-26 [17234737.001]
  • [Cites] Blood. 1990 Dec 15;76(12):2462-5 [2265242.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Apr;9(4):215-33 [12720215.001]
  • [Cites] Blood. 2002 Jul 1;100(1):59-66 [12070009.001]
  • (PMID = 19396412.001).
  • [ISSN] 1432-1289
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 40
  •  go-up   go-down


91. Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Nishihori T, Field T, Perkins J, Perez L, Fernandez HF: Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. J Hematol Oncol; 2010;3:36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia.
  • Optimal conditioning therapy for hematopoietic cell transplantation (HCT) in acute myelogenous leukemia (AML) remains undefined.
  • However, multivariable analysis did not demonstrate significant differences in overall survival (p = 0.78) or non-relapse mortality (p = 0.6) according to conditioning regimen delivered.
  • [MeSH-major] Busulfan / pharmacokinetics. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Transplantation Conditioning

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Blood Marrow Transplant. 2002;8(9):468-76 [12374451.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):957-69 [19611402.001]
  • [Cites] Bone Marrow Transplant. 2003 Jun;31(12):1089-95 [12796788.001]
  • [Cites] Blood. 2003 Aug 1;102(3):820-6 [12676781.001]
  • [Cites] Blood. 2004 Aug 1;104(3):857-64 [15073038.001]
  • [Cites] Ann Intern Med. 1993 Feb 15;118(4):255-67 [8420443.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • [Cites] Bone Marrow Transplant. 1996 Feb;17(2):225-30 [8640171.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3599-604 [9808553.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5728-38 [16009946.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5675-87 [16110027.001]
  • [Cites] Cancer. 2005 Nov 1;104(9):1931-8 [16178004.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56 [16338616.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9387-93 [16314618.001]
  • [Cites] Leukemia. 2006 Feb;20(2):322-8 [16307018.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1092-9 [16551971.001]
  • [Cites] Bone Marrow Transplant. 2007 Sep;40(6):541-7 [17637692.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):577-84 [18086801.001]
  • [Cites] Bone Marrow Transplant. 2008 Apr;41(8):721-7 [18176613.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jun;14(6):672-84 [18489993.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Sep;14(9):993-1003 [18721762.001]
  • [Cites] Blood. 2003 Mar 1;101(5):2043-8 [12406916.001]
  • (PMID = 20925957.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine
  • [Other-IDs] NLM/ PMC2958877
  •  go-up   go-down


92. Ruggeri A, Ciceri F, Gluckman E, Labopin M, Rocha V, Eurocord and Acute Leukemia Working Party of the European Blood and Marrow Transplant Group: Alternative donors hematopoietic stem cells transplantation for adults with acute myeloid leukemia: Umbilical cord blood or haploidentical donors? Best Pract Res Clin Haematol; 2010 Jun;23(2):207-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternative donors hematopoietic stem cells transplantation for adults with acute myeloid leukemia: Umbilical cord blood or haploidentical donors?
  • Use of allogeneic transplantation for patients with acute myeloid leukemia (AML) depends mainly on the risk of the disease, and HLA matched donor availability.
  • In patients with high-risk leukemia, in the absence of a HLA (human leukocyte antigen) matched donor, alternative donors such as unrelated umbilical cord blood (UCB) or haploidentical donor (haplo) have been currently used.
  • However, in spite of higher incidence of graft failure in UCB transplatation recipients and higher relapse incidence after haplo transplants, final outcomes seem to be comparable with HLA matched unrelated hematopoietic stem cell transplantation (bone marrow or peripheral blood).
  • Here we review the current status of UCBT and haplo transplants to treat adults with high-risk acute myeloid leukemia and we discuss the main issues associated with the use of both hematopoietic stem cell transplant approaches.
  • [MeSH-major] Cord Blood Stem Cell Transplantation / methods. HLA Antigens. Hematopoietic Stem Cell Transplantation / methods. Histocompatibility. Leukemia, Myeloid, Acute / therapy. Peripheral Blood Stem Cell Transplantation / methods. Tissue Donors


93. Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G: Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood; 2006 May 15;107(10):4011-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).
  • Mutations of the nucleophosmin (NPM1) gene have recently been described in patients with acute myeloid leukemia (AML).
  • The analysis of the clinical impact in 4 groups (NPM1 and FLT3-ITD single mutants, double mutants, and wild-type [wt] for both) revealed that patients having only an NPM1 mutation had a significantly better overall and disease-free survival and a lower cumulative incidence of relapse.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Mutation. Nuclear Proteins / genetics


94. Martínez C, Solano C, Ferrá C, Sampol A, Valcárcel D, Pérez-Simón JA, Spanish Group for Stem Cell Transplantation (Grupo Español de Trasplante Hemopoyético y Terapia Celular): Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study. Biol Blood Marrow Transplant; 2009 May;15(5):639-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study.
  • We conducted a phase II trial to investigate the safety and efficacy of alemtuzumab in treating steroid-refractory acute graft-versus-host disease (aGVHD) grade II or higher after stem cell transplantation.
  • All 10 patients died (7 resulting from aGVHD progression, 2 from severe infection, and 1 from to leukemia relapse), at a median of 40 days (range, 4 to 88 days) after alemtuzumab treatment.
  • [MeSH-minor] Acute Disease. Adult. Aged. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / toxicity. Cause of Death. Female. Gastrointestinal Diseases. Hematopoietic Stem Cell Transplantation / adverse effects. Humans. Liver Diseases. Male. Middle Aged. Opportunistic Infections. Salvage Therapy. Skin Diseases. Steroids / therapeutic use. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19361757.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / Steroids; 3A189DH42V / alemtuzumab
  •  go-up   go-down


95. Haining WN, Cardoso AA, Keczkemethy HL, Fleming M, Neuberg D, DeAngelo DJ, Stone RM, Galinsky I, Silverman LB, Sallan SE, Nadler LM, Guinan EC: Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia. Exp Hematol; 2005 Mar;33(3):286-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia.
  • OBJECTIVES: We and others have shown that B cell precursor acute lymphoblastic leukemia cells (ALL) stimulated with CD40 ligand become efficient antigen-presenting cells (APC) capable of expanding autologous, tumor-specific T cells from patients.
  • Five patients died or progressed before vaccination, suggesting that rapid disease progression limits vaccination in patients with relapse disease, thus limiting clinical translation.
  • CONCLUSION: Autologous tumor vaccination at a time of ALL relapse is not feasible.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Immunotherapy, Adoptive. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15730852.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / K08HL72750; United States / NCI NIH HHS / CA / P01CA68484
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD40; 0 / Cancer Vaccines
  •  go-up   go-down


96. Pieters R, Carroll WL: Biology and treatment of acute lymphoblastic leukemia. Hematol Oncol Clin North Am; 2010 Feb;24(1):1-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biology and treatment of acute lymphoblastic leukemia.
  • Acute lymphoblastic leukemia (ALL), the most common type of cancer in children, is a heterogeneous disease in which many genetic lesions result in the development of multiple biologic subtypes.
  • The many national or institutional ALL therapy protocols in use tend to stratify patients in a multitude of different ways to tailor treatment to the rate of relapse.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20113893.001).
  • [ISSN] 1558-1977
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 102
  •  go-up   go-down


97. Ferrara F, Fazi P, Venditti A, Pagano L, Amadori S, Mandelli F: Heterogeneity in the therapeutic approach to relapsed elderly patients with acute myeloid leukaemia: a survey from the Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Acute Leukaemia Working Party. Hematol Oncol; 2008 Jun;26(2):104-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterogeneity in the therapeutic approach to relapsed elderly patients with acute myeloid leukaemia: a survey from the Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Acute Leukaemia Working Party.
  • The percentage of long-term survivors in acute myeloid leukaemia (AML) in the elderly does not exceed 10-15% of patients enrolled into clinical trials because of lower complete remission (CR) rates and higher incidence of relapse.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Leukemia, Myeloid, Acute / therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18271064.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


98. Shimoni A, Hardan I, Shem-Tov N, Rand A, Herscovici C, Yerushalmi R, Nagler A: Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan. Leukemia; 2007 Oct;21(10):2109-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan.
  • Grade III-IV organ toxicity occurred in 31 and 53% of FB and FM recipients (P=0.005) and acute graft-versus-host disease grade II-IV in 33 and 53%, respectively (P=0.01).
  • Non-relapse mortality rate (NRM) was 16 and 40%, respectively (P=0.003).
  • Similarly, patients transplanted in active disease experienced higher NRM with FM, however lower relapse rates resulted in equivalent OS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Busulfan / administration & dosage. Hematopoietic Stem Cell Transplantation / methods. Leukemia / therapy. Melphalan / administration & dosage. Transplantation Conditioning / methods. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690701.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine; Q41OR9510P / Melphalan
  •  go-up   go-down


99. Ek T, Mellander L, Abrahamsson J: Interferon gamma and tumour necrosis factor alpha in relation to anaemia and prognosis in childhood cancer. Acta Paediatr; 2005 Apr;94(4):435-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study examined whether the initial plasma levels of tumour necrosis factor alpha (TNFalpha) and interferon gamma (IFNgamma) in 131 children with newly diagnosed cancer were associated with haematopoietic suppression, and whether plasma levels of TNFalpha or haemoglobin at diagnosis affects long-term prognosis in childhood acute lymphoblastic leukaemia (ALL).
  • Neither TNFalpha levels nor Hb levels were associated with increased risk of ALL relapse.
  • [MeSH-minor] Child. Hemoglobins / analysis. Humans. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Prognosis

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16092457.001).
  • [ISSN] 0803-5253
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Tumor Necrosis Factor-alpha; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


100. Muñoz A, Diaz-Heredia C, Diaz MA, Badell I, Verdeguer A, Martinez A, Gomez P, Perez-Hurtado JM, Bureo E, Fernandez-Delgado R, Gonzalez-Valentin ME, Maldonado MS: Allogeneic hemopoietic stem cell transplantation for childhood acute lymphoblastic leukemia in second complete remission-similar outcomes after matched related and unrelated donor transplant: a study of the Spanish Working Party for Blood and Marrow Transplantation in Children (Getmon). Pediatr Hematol Oncol; 2008 Jun;25(4):245-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hemopoietic stem cell transplantation for childhood acute lymphoblastic leukemia in second complete remission-similar outcomes after matched related and unrelated donor transplant: a study of the Spanish Working Party for Blood and Marrow Transplantation in Children (Getmon).
  • Characteristics at diagnosis and initial and after relapse antileukemic treatment were similar in the related donor (RD) and the unrelated donor (UD) groups.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy






Advertisement